

# JESSICA CHUBAK

*Curriculum vitae*

## BIOGRAPHICAL INFORMATION

Jessica Chubak

Kaiser Permanente Washington Health Research Institute

1730 Minor Avenue, Suite 1360

Seattle, WA 98101-1466

Phone: 206-287-2556

Fax: 206-287-2871

E-mail: [Jessica.Chubak@kp.org](mailto:Jessica.Chubak@kp.org)

Website: <https://www.kp.washingtonresearch.org/our-research/our-scientists/chubak-jessica>

ORCID: <https://orcid.org/0000-0003-1630-9021>

## EDUCATION

Bachelor of Arts in Molecular Biology, *summa cum laude*, May 2000

Pomona College, Claremont, California

Master of Bioethics and Health Law, awarded with distinction, March 2002

University of Otago, Dunedin, New Zealand

Doctor of Philosophy in Epidemiology, August 2007

University of Washington, Seattle, Washington

## LICENSURE

Not applicable

## PROFESSIONAL POSITIONS

### Current position

Manager, Investigative Science Division, August 2022 – present

Kaiser Permanente Washington Health Research Institute, Kaiser Foundation Health Plan of Washington, Seattle, Washington

Senior Investigator, September 2018 – present\*

Kaiser Permanente Washington Health Research Institute, Kaiser Foundation Health Plan of Washington, Seattle, Washington

Affiliate Professor, July 2020 – present

Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington

### Past positions

Interim Director, Investigative Science Division, August 2024 – September 2025

Kaiser Permanente Washington Health Research Institute, Kaiser Foundation Health Plan of Washington, Seattle, Washington

Associate Scientific Investigator, May 2013 – September 2018\*

Kaiser Permanente Washington Health Research Institute, Kaiser Foundation Health Plan of Washington, Seattle, Washington

Assistant Scientific Investigator, October 2007 – April 2013  
Group Health Research Institute, Group Health Cooperative, Seattle, Washington

Affiliate Associate Professor, June 2014 – June 2020  
Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington

Affiliate Assistant Professor, 2008 – 2013  
Department of Epidemiology, University of Washington School of Public Health, Seattle, Washington

Epidemiologic Methods Teaching Assistant, 2006 – 2007  
University of Washington School of Public Health and Community Medicine, Seattle, Washington

Research Assistant, 2002 – 2006  
Fred Hutchinson Cancer Research Center, Seattle, Washington

Bioethics Tutor (Section Lecturer), 2001 – 2002  
University of Otago Medical School, Dunedin, New Zealand

*\*Kaiser Permanente acquired Group Health in February 2017, at which point Group Health Research Institute became Kaiser Permanente Washington Health Research Institute.*

## **HONORS, AWARDS, SCHOLARSHIPS**

Tileston Physics 1 Prize, top student in introductory physics course, Pomona College, 1997

Pomona College Scholar, 1997 – 1999

Phi Beta Kappa, Pomona College, 1999

Phi Beta Kappa Award, awarded for quality of scholarship and promise of future distinction, 2000  
*Summa cum laude*, Pomona College, 2000

Rena Gurley Archibald High Scholarship Prize, awarded to college's highest ranked graduate, 2000

Fulbright Graduate Student Award to New Zealand, 2001 – 2002

Master's degree awarded with distinction, 2002

NIH Cancer Epidemiology and Biostatistics Training Program pre-doctoral trainee, 2003 – 2006

Presenter, Student Workshop, Society for Epidemiologic Research, Toronto, Canada, 2005

International Society for Pharmacoepidemiology, travel scholarship, 2006

American Society of Preventive Oncology, abstract among top 16 at annual meeting, 2009

Cancer Research Network (CRN) Scholars Program participant, 2009 – 2011

American Society of Preventive Oncology, honorable mention for poster, annual meeting, 2012

International Cancer Screening Network, travel scholarship, 2012

Participant and presenter, National Cancer Institute, Division of Cancer Control and Prevention, New Grantee Workshop, 2014.

Extraordinary Principal Investigator Award, Kaiser Permanente Washington Health Research Institute, 2017

Most grant funding in past year at Associate Investigator level, Kaiser Permanente Washington Health Research Institute, 2017

Most grant publications in past year at Associate Investigator level, Kaiser Permanente Washington Health Research Institute, 2017

Nominee for Outstanding Faculty Mentor Award, 2016-2018

Recipient of Outstanding Faculty Mentor Award, 2019

Nominee for Outstanding Mentor of Scientists Award, 2022, 2023

## **PROFESSIONAL ACTIVITIES AND SERVICE**

### **Committees**

Member, Student Health Advisory Committee, Pomona College, 1996 – 1997

Member, Epidemiology Seminar Planning Committee, University of Washington, 2002 – 2003

Co-director & co-founder, Forum on Science Ethics and Policy (FOSEP), University of Washington, 2004 – 2007

Member, Graduate Process Advisory Committee, University of Washington, 2004 – 2006

Member, Research Ethics Education Oversight Committee, Fred Hutchinson Cancer Research Center, 2003 – 2007

Coordinator, Cancer Researchers Group, Group Health Research Institute, 2007 – 2010

Member, Postdoctoral Fellow Search Committee, Group Health Center for Health Studies, 2008

Member, Faculty Retreat Planning Committee, Group Health Center for Health Studies, 2008

Member, Scientific Policy Committee, Group Health Research Institute, 2009 – 2013

Co-chair, Scientific Policy Committee, Group Health Research Institute, 2010 – 2011

Member, Strategic Planning Steering Committee, Group Health Research Institute, 2011

Co-chair, Scientific Policy Committee, Group Health Research Institute, 2012 – 2013

Member, Technical Specialist Hiring Committee, Group Health Research Institute, 2013

Member, American Society of Preventive Oncology Junior Members Organizing Committee, 2013

Member, Biostatistics Investigator Search Committee, Group Health Research Institute, 2014 – 2015

Member, Data & Informatics Strategy Committee, Group Health Research Institute 2014 – present

Member, Scientific Advisory Committee, Group Health Research Institute, 2015 – present

Member, Colorectal Cancer Screening Guideline Team, Group Health, 2015 – 2017

Member, Director of Research IT Search Committee, Group Health Research Institute, 2016

Member, Policy around Purchased Services for Science Workgroup, Group Health Research Institute, 2016

Member, Oversight Processes Related to Sharing Data, Specimens, and Derivatives Workgroup, Kaiser Permanente Washington Health Research Institute, 2017

Member, Colorectal Cancer Screening Guideline Team, Kaiser Permanente Washington, 2019 – present

Member, Policy on Calendaring/Email/Meeting Standards Workgroup, Kaiser Permanente Washington Health Research Institute, 2020

Member, Effort Management Workgroup, Kaiser Permanente Washington Health Research Institute, 2020

Member, Equity Team / Faculty Equity Team Subcommittee (FACET), Kaiser Permanente Washington Health Research Institute, 2020 – 2021

Member, Manager, Research Project Management Office Search Committee, Kaiser Permanente Washington Health Research Institute, 2021

Co-chair, Investigator Search Committee, Kaiser Permanente Washington Health Research Institute, 2022

Co-chair, Project Roles Workgroup, Kaiser Permanente Washington Health Research Institute, 2024

Member, New Technologies Workgroup, International Cancer Screening Network, 2024 – present

Member and Hiring Manager, Investigator Search Committee, Kaiser Permanente Washington Health Research Institute, 2024 – present

Chair, Promotions Committee, Kaiser Permanente Washington Health Research Institute, 2024 – present

### **Study section and grant reviews**

Reviewer, Native Elder Research / Resource Center for Minority Aging Research (NERC/RCMAR) Native Investigator Program, mock NIH review section, University of Washington, 2008

Reviewer, Group Health Partnership for Innovation, 2008, 2010

Reviewer, Cancer Research Network Pilot Projects, 2008 – 2009

Reviewer, Institute of Translational Health Sciences Community/Practice-Based Research Activity Funding, 2010

Reviewer, Cancer Research Network Scholars Program, 2013

Reviewer, Patient Centered Outcomes Research Institute, PCORI Cycle II, Comparative Effectiveness Research Panel A, 2013

Reviewer, Emerging Leaders In Science & Society Fellowship, American Association for the Advancement of Science, 2014

Reviewer, Diabetes UK, 2014

Reviewer, National Institutes of Health, Cancer, Heart, and Sleep Epidemiology Panel A, October 2015, June 2017

Reviewer, National Institutes of Health, Special Emphasis Panel, Fellowships: Risks, Prevention and Health Behavior, July 2020

Reviewer, National Institutes of Health, Special Emphasis Panel, Human-Animal Interaction, April 2021

Co-chair and reviewer, National Institutes of Health, Special Emphasis Panel, Human-Animal Interaction, April 2022

Reviewer, Veterans Administration, HSR-6 (Long-Term Care, Aging and Support Services), August 2022, March 2023

### **Organization of conferences and symposia**

Co-organizer, public forum. “Stem Cells: The Science, The Policy, Possibilities.” University of Washington. Seattle, Washington, 2004.

Planning committee member, School of Public Health and Community Medicine’s 2nd Annual Symposium on Teaching and Learning. University of Washington, Seattle, Washington, 2005.

Co-organizer, symposium. “Scientists, the Public, and Policy-makers in Dialogue: Principles and Applications.” American Association for the Advancement of Science. St. Louis, Missouri, 2006.

Co-chair, Survivorship Special Interest Group breakfast session. “Identifying key questions to advance research and practice in cancer survivorship follow-up care.” American Society of Preventive Oncology. Tampa, Florida, 2009.

Chair, spotlight session. “Opportunities and Challenges in Studying Outcomes of Cancer.” Society for Epidemiologic Research. Seattle, Washington, 2010.

- Planning committee member, career development session. “Careers in cancer prevention: what you may not see from inside your academic department.” American Society of Preventive Oncology. Washington DC, 2012.
- Co-chair. “Cancer II – Cancer Research Network.” HMO Research Network Meeting. Seattle, Washington, 2012.
- Co-chair. “Breast Cancer: Risk Prediction, Screening, and Behavior Modification.” American Society of Preventive Oncology. Washington DC, 2012.
- Co-chair, career development session. “Transitioning to independence and maintaining a research career in the new funding climate.” American Society of Preventive Oncology Memphis, Tennessee, 2013.
- Scientific Planning Committee member, International Cancer Screening Network meeting, Rotterdam, the Netherlands, 2015.
- Co-organizer and moderator. “Individualized screening.” International Cancer Screening Network meeting, Rotterdam, the Netherlands, 2015.
- Co-chair, symposium. “Epidemiology and implementation science: Designing and conducting research with the real world in mind.” Society for Epidemiologic Research, Denver, Colorado, 2015.
- Co-chair, symposium. “Moving beyond numbers: how qualitative data can complement your quantitative study.” Epidemiology Congress of the Americas, Miami, Florida, 2016.
- Co-chair, symposium. “Epidemiology's next 50 years through the lens of the last 50.” Society for Epidemiologic Research, Seattle, Washington, 2017.
- Co-chair, symposium. “Thinking beyond diagnosis, procedure, and drug codes: Shaping the future of epidemiologic research using electronic healthcare databases.” Society for Epidemiologic Research, Baltimore, Maryland, 2018.
- Co-host, symposium. “What problems can electronic health records solve? The strengths and pitfalls of EHR data.” 7<sup>th</sup> Kolokotronis Symposium on Data Science, Harvard University, Boston, Massachusetts, 2019.
- Co-chair, symposium. “Brain-"storming" approaches to studying climate change and health.” Society for Epidemiologic Research, Portland, Oregon, 2023.

### **Manuscript reviewer**

- Ad hoc reviewer, Pharmacoepidemiology and Drug Safety, 2008 – present (honored as one of “best reviewers” in 2017)
- Ad hoc reviewer, Cancer Causes and Control, 2008 – present
- Ad hoc reviewer, Cancer Epidemiology Biomarkers & Prevention, 2008 – present
- Ad hoc reviewer, American Journal of Epidemiology, 2008 – present
- Ad hoc reviewer, Breast Cancer Research and Treatment, 2011 – present
- Ad hoc reviewer, European Journal of Public Health, 2011 – present
- Ad hoc reviewer, Medical Care, 2011 – present
- Ad hoc reviewer, Cancer Epidemiology, 2011 – present
- Ad hoc reviewer, Journal of Oncology Practice, 2012 – present
- Ad hoc reviewer, European Journal of Gastroenterology & Hepatology, 2012 – present
- Ad hoc reviewer, Journal of Clinical Epidemiology, 2012 – present
- Ad hoc reviewer, Health Services Research, 2013 – present
- Ad hoc reviewer, Journal of the National Cancer Institute, 2014 – present
- Ad hoc reviewer, Annals of Epidemiology, 2014 – present

Ad hoc reviewer, *Epidemiologic Methods*, 2014 – present  
Ad hoc reviewer, *British Journal of Cancer*, 2014 – present  
Ad hoc reviewer, *JAMA Oncology*, 2015 – present  
Ad hoc reviewer, *BMJ Open*, 2015 – present  
Ad hoc reviewer, *Psycho-Oncology*, 2016 – present  
Ad hoc reviewer, *Journal of Cancer Survivorship*, 2016 – present  
Ad hoc reviewer, *American Journal of Preventive Medicine*, 2016 – present  
Ad hoc reviewer, *Preventive Medicine*, 2017 – present  
Ad hoc reviewer, *Gastroenterology*, 2017 – present  
Ad hoc reviewer, *JMIR mHealth and uHealth*, 2018 – present  
Ad hoc reviewer, *Integrative Cancer Therapies*, 2019 – present  
Ad hoc reviewer, *PLOS ONE*, 2019 – present  
Ad hoc reviewer, *Cancer*, 2019 – present  
Ad hoc reviewer, *JAMA Network Open*, 2019 – present  
Ad hoc reviewer, *JAMA*, 2020 – present  
Ad hoc reviewer, *Observational Studies*, 2022 – present  
Ad hoc reviewer, *Pediatrics*, 2022 – present  
Ad hoc reviewer, *Epidemiology*, 2022 – present

#### **Abstract reviews for national conferences**

Abstract reviewer, 2012 HMO Research Network Annual Meeting  
Abstract reviewer, 2012 American Society of Preventive Oncology Annual Meeting  
Abstract reviewer, 2013 Society for Epidemiologic Research Annual Meeting  
Abstract reviewer, 2015 International Cancer Screening Network Meeting  
Poster judge, 2018 Society for Epidemiologic Research Annual Meeting  
Poster judge, 2020 Society for Epidemiologic Research Annual Meeting  
Poster judge, 2021 Society for Epidemiologic Research Annual Meeting  
Abstract reviewer, 2022 Society for Epidemiologic Research Annual Meeting

#### **Editorial responsibilities**

Member, Editorial Board, *Journal of Cancer Survivorship*, 2016 – present  
Member, Editorial Advisory Board, *Cancer* (publication of American Cancer Society), 2024 – present  
Associate Editor, *Journal of the National Cancer Institute*, 2024 – present

#### **Membership in professional organizations**

American Society of Preventive Oncology, 2008 – 2023  
Society for Epidemiologic Research, 2009 – present  
International Society for Pharmacoepidemiology, 2011

#### **Other professional service**

Panelist, *Epidemiology 584 Career Panel*, University of Washington, 2009  
Panelist, “Breakfast with the Experts” roundtable, Society for Epidemiologic Annual Meeting 2020 (virtual)

Participant, Virtual Roundtable, Developing and Applying Algorithm Certainty Tool Kit (ACE IT) in Major Adverse Cardiovascular Events (MACE), Reagan-Udall Foundation for the FDA, March 2022.  
Panelist, Mentoring Panel, Kaiser Permanente Washington Health Research Institute, 2024.

### **Community service**

Panelist, Whitman Middle School Annual Science Fair, 2009 – 2011  
Speaker, Eckstein Middle School, Student Interest Assessment (college/career planning), 2013  
Participant, Epi Expo, University of Washington, 2014  
Volunteer (Dental Admin), Seattle King County Clinic, October 2016  
Volunteer (General Support), Seattle King County Clinic, October 2017  
Tutor, Seattle Youth Tutoring Program, 2018, 2020 – 2021  
Co-organizer, High School Student Outreach Day, Kaiser Permanente Washington Health Research Institute, October 2018  
Volunteer (Data Moderator), FindTheMasks.org, March – April 2020  
Volunteer, COVID-19 Staffing Office, Kaiser Permanente Washington, January 2021

### **RESEARCH**

#### **Completed projects**

1. Trainee: Cancer Epidemiology and Biostatistics Training Grant, 2003-2006 (Principal Investigator: Noel S. Weiss). T32CA09168 funded by the National Cancer Institute.
2. Analyst (15% effort): Medications and Colorectal Cancer Risk, 8/1/2004-7/31/2008 (Principal Investigator: Denise Boudreau). 5R03CA110851-02 funded by the National Cancer Institute. Total direct costs \$100,000.
3. Co-investigator (10% effort, 1 year): Institutional and Clinical Translational Science Award, 9/17/2007-5/31/2012 (Principal Investigator: Nora Dsis). 5UL1RR025014 funded by National Institutes of Health. Group Health direct costs: \$1,319,532.
4. Co-investigator (10% effort): Center for Health Studies Value Metrics Program, 1/1/2008-12/31/2008 (Principal Investigator: Paul Fishman). Funded by Group Health Center for Health Studies. Total direct costs: \$226,591.
5. Principal Investigator (15% effort): Organization of Cancer Survivorship Care in Community-based Delivery Systems, 1/1/2009-12/31/2009. Funded by Group Health Center for Health Studies. Direct costs: \$51,575.
6. Co-investigator (10% effort): Web-Based, Patient-Centered Approach to CVD Risk-Factor Management and Reduction, 9/30/2006-6/30/2011 (Principal Investigator: Jeffery Henderson). 5U01HL087422 funded by the National Heart, Lung, and Blood Institute. Group Health direct costs: \$66,569.
7. Principal Investigator (5% effort): Medicare Advantage SNP Evaluation, 12/1/2007-6/30/2011. Funded by Group Health Research Institute. Direct costs: \$367,707.
8. Principal Investigator (15% effort): Cognitive Function and Breast Cancer Care. Pilot study funded by Northwest Roybal Center: Improving Healthcare for Cognitively Impaired Elders and Their Caregivers, 9/30/2009-8/31/2011 (Principal Investigator: Linda Teri). 1P30AG0345592 funded by the National Institute on Aging. Direct costs of pilot: \$66,569.

9. Co-investigator (2% effort): Prevention of Ovarian Cancer in Women Participating in Mammography, 9/30/2007-9/29/2011 (Principal Investigator: Nicole Urban) 5R18DP001142 funded by the Centers for Disease Control and Prevention. Group Health direct costs: \$78,125.
10. Co-investigator (effort contributed): Feasibility study of pre-invasive HPV-related anogenital neoplasia surveillance in western Washington state, 10/1/2008-12/31/2011 (Principal Investigator: Stephen Schwartz) funded by Merck. Group Health direct costs: \$37,910.
11. Co-investigator (effort contributed): Natural Language Processing for Cancer Research Network Surveillance Studies, 9/30/2009-8/31/2011 (Principal Investigator: David Carrell). RC1CA146917 funded by the National Cancer Institute. Direct costs: \$688,161.
12. Principal Investigator (20% effort): Algorithms to Identify Second Breast Cancer Events from Electronic Data, 1/04/2010-12/31/2011. R21CA143242 funded by the National Cancer Institute. Direct costs: \$270,259.
13. Principal Investigator (5% effort): Risk of non-Hodgkin's Lymphoma in Relation to Tricyclic Antidepressant Use, 9/01/2011-8/31/2012: R03CA156357 funded by the National Cancer Institute. Direct costs: \$50,000.
14. Co-investigator (5% effort): Cancer Research Network Across Health Care Systems – Infrastructure, 5/1/2007-4/30/2012 (Principal Investigator: Ed Wagner) 2U19CA079689 funded by the National Cancer Institute. Direct costs: \$15,362,544.
15. Co-investigator (10% effort). Systems of support (SOS) to Increase Colorectal Cancer Screening and Follow-up (Principal Investigator: Beverly B. Green), 7/1/2007-5/31/2013. R01CA121125 funded by the National Cancer Institute. Direct costs: \$2,301,470.
16. Co-investigator (5% effort): Short and Long-Term Effects of a Positive CRCS Test and Longitudinal Survival Analysis of CRCS Screening Rates - Administrative Supplement, 8/1/2009-7/31/2011 (Principal Investigator: Beverly Green). 3R01CA121125-03S1 funded by the National Cancer Institute. Direct costs: \$331,890.
17. Co-investigator and Methods Core co-lead (20% effort): SEARCH: Cancer Screening Effectiveness And Research in Community-based Healthcare, 9/30/2009-8/31/2012 (Principal Investigators: Diana Buist and Chyke Doubeni). 1UC2CA148576 funded by the National Cancer Institute. Direct costs: \$3,619,324.
18. Co-investigator (10% effort): Commonly Used Medications and Breast Cancer Recurrence, 9/1/2007-07/31/2012 (Principal Investigator: Denise Boudreau). 1R01CA1205621 funded by the National Cancer Institute. Direct costs \$1,141,602.
19. Co-investigator (2% effort): Commonly Used Medications and Breast Cancer Recurrence-Administrative Supplement, 9/29/2009-8/31/2012 (Principal Investigator: Denise Boudreau). R206130930 funded by the National Cancer Institute. Direct costs: \$199,721.
20. Principal Investigator (15% effort): Relationship between health care and health status in people with Type 1 diabetes, 1/1/2012-3/31/2013. Funded by Group Health Research Institute Development Fund. Direct costs: \$100,849.
21. Site Principal Investigator (5% effort): LiveSTRONG 2012 Cancer Survivorship Survey: Collaboration with the HMO Cancer Research Network, 12/12/2012-10/31/2014. Funded by LiveSTRONG Foundation (Principal Investigator: Larissa Nekhlyudov). Group Health direct costs: \$76,973.

22. Co-investigator (2% effort): Testing an Optimal Model of Patient-Centered Cancer Care: CRN Clinical Communication Research Center, 9/30/2008-8/31/2014 (Principal Investigator: James Dearing). P20CA137219 funded by the National Cancer Institute. Group Health direct costs: \$1,022,474.
23. Lead Investigator (20% effort): Evidence-Based Practice Center Task Order #2, 2/1/2013-11/30/2014. Funded by Agency for Healthcare Research and Quality contract to Evelyn Whitlock. Group Health direct costs: \$218,924.
24. Co-investigator (15% effort): Comparative Effectiveness of Preoperative Breast MRI on Surgery and Outcomes, 9/1/2011-7/31/2016 (Principal Investigator: Tracy Onega). R01CA149365 funded by the National Cancer Institute. Group Health direct costs: \$616,368.
25. Co-investigator (concurrent effort). Statistical Methods for Estimation of Benefits & Harms of Repeat Cancer Screening, 1/1/2014-12/31/2015 (Principal Investigator: Rebecca Hubbard). R03CA182986 funded by the National Cancer Institute. Direct costs: \$100,000.
26. Principal Investigator (9% effort): Developing Trials of Animal-Assisted Activities for Youth with Cancer, 4/1/2013-3/31/2015. 1R03CA169573-01A1 funded by the National Cancer Institute. Direct costs: \$91,535.
27. Principal Investigator (concurrent effort). Positioning the PORPOISE Study for R01 funding, 1/1/2014-12/31/2016. Funded by Group Health Research Institute Development Fund. Direct costs: \$30,434.
28. Principal Investigator (15%). Cancer Survivor Survey on Electronic Cigarettes and Symptom Burden, 1/1/2016-12/31/2016. Funded by Group Health Research Institute Development Fund. Direct costs: \$128,729.
29. Site Principal Investigator (10% effort): A Cohort Study of Sessile Serrated Polyps and Subsequent Colorectal Neoplasia, 4/22/2013-3/31/2017 (Principal Investigator: Polly Newcomb). R01CA168338 funded by the National Cancer Institute. Group Health direct costs: \$772,199.
30. Principal Investigator (10% effort): Developing expertise and methods to support a trial of therapy dog visits in pediatric oncology. 10/1/2017 – 12/31/2017. Funded by Kaiser Permanente Washington Health Research Institute Development Fund. Direct costs: \$11,323.
31. Principal Investigator (8% effort): Sessile Serrate Polyp study completion, 10/1/2017 – 12/31/2017. Funded by Kaiser Permanente Washington Health Research Institute Development Fund. Direct costs: \$9,892.
32. Principal Investigator and Project 2 Lead (30% effort): SuCCESS: Studying Colorectal Cancer: Effectiveness of Screening Strategies, 9/1/2011-5/31/2018. U54CA163261 funded by the National Cancer Institute. Direct costs: \$3,594,020. [Chubak replaced Rutter as PI in 2014]
33. Multiple Principal Investigator (5% effort): SuCCESS: Studying Colorectal Cancer: Effectiveness of Screening Strategies – Cervical Cancer Unit, 9/20/2011-5/31/2018 (Principal Investigators: Aruna Kamineni and Jessica Chubak). U54CA163261 funded by the National Cancer Institute. Direct costs: \$812,340.
34. Multiple Principal Investigator (20% effort): SuCCESS: Studying Colorectal Cancer: Effectiveness of Screening Strategies – Administrative supplement, 6/1/2016 – 5/31/2018 (Principal Investigators: Jessica Chubak and Aruna Kamineni). U54CA163261 funded by the National Cancer Institute. Direct costs: \$424,800.

35. Principal Investigator (15% effort): Commonly Used Medications and Colorectal Cancer Recurrence, 9/19/2013 – 7/31/2018. R01CA172973 funded by the National Cancer Institute. Direct costs: \$1,562,771.
36. Principal Investigator (1% effort). Critical Support and Expansion of a Trial of Therapy Dog Visits in Pediatric Oncology, 1/1/2018-12/31/2018. Funded by the Kaiser Permanente Washington Health Research Institute Development Fund. Direct costs: \$37,980.
37. Multiple Principal Investigator (concurrent effort). Leveraging machine learning to improve risk prediction for chemotherapy induced neuropathy. 10/1/2018 – 12/31/2018. Cancer Research Network Catalyst Funds. Kaiser Permanente Washington direct costs: \$1,329.
38. Site Principal Investigator (10% effort): Weight loss as a predictor of cancer in primary care, 6/22/2017 – 12/31/2018 (Principal Investigator: Brian Nicholson). Funded by United Kingdom National Institute for Health Research. Kaiser Permanente Washington direct costs: \$25,000.
39. Site Principal Investigator, Informatics Core co-lead (20% effort): CRN4: Cancer Research Resources & Collaboration in Integrated Health Care Systems, 9/25/2012-2/28/2019 (Principal Investigator: Larry Kushi). 1U24CA171524 funded by the National Cancer Institute. Kaiser Permanente Washington direct costs: \$1,607,111.
40. Co-investigator (2% effort). Competitive Revision: Systems of support (SOS) to Increase Colorectal Cancer Screening and Follow-up, 9/1/2013-6/30/2019 (Principal Investigator: Beverly B. Green). R01CA121125 funded by the National Cancer Institute. Direct costs: \$2,314,253.
41. Co-investigator (2% effort). Competitive Revision: Systems of support (SOS) to Increase Colorectal Cancer Screening and Follow-up Administrative Supplement: Financial Incentives for Completion of Colorectal Cancer (CRC) Screening for Priority Populations (Principal Investigator: Beverly B. Green), 9/1/2013-6/30/2019. 1R01CA121125 funded by the National Cancer Institute. Direct costs: \$93,528.
42. Multiple Principal Investigator (20% effort): ReCAPSE: Recurrence using Claims And PROs for SEER Expansion. 9/25/2017 – 2/28/2020 (Principal Investigators: Ruth Etzioni, Jessica Chubak, and Bin Huang). UG3CA218909 funded by the National Cancer Institute. Total direct costs: \$672,148. Kaiser Permanente Washington direct costs: \$97,919.
43. Site Principal Investigator (18% effort). Causal Analyses of Nested Case-Control Studies for Comparative Effectiveness Research. 3/1/2018 – 2/28/2020 (Principal Investigator: Goodarz Danaei). Funded by Patient-Centered Outcomes Research Institute. Kaiser Permanente Washington direct costs: \$161,323.
44. Co-investigator (4% effort): Harms of hepatocellular carcinoma screening in patients with cirrhosis, 8/1/2017-7/31/2022 (Principal Investigator: Amit Singal). R01CA212008 funded by the National Cancer Institute. Kaiser Permanente Washington year 1-2 direct costs: \$20,289.
45. Site Principal Investigator (10% effort). Improving confounder control in EHR-based studies of cancer epidemiology. 1/1/2019 – 12/31/2020 (Principal Investigator: Rebecca A. Hubbard). R21CA227613-01A1 funded by the National Cancer Institute. Kaiser Permanente direct costs: \$67,246.
46. Principal Investigator (10% effort). Heart failure algorithm. 9/1/2018 – 2/28/2021 funded by Amgen. Direct costs: \$270,071.

47. Co-investigator (contributed). Paws Unite: Prototyping a Social Connection Innovation. 6/1/2021–12/31/2021 (Principal Investigator: Leah Tuzzio). Funded by the KPWHRI Small Grants Program. Direct costs: \$7,620.
48. Principal Investigator (2-12% effort): Psychological benefits and potential pathogen transmission in hospitalized pediatric oncology patients receiving therapy dog visits: a randomized controlled trial, 5/1/2017 – 4/30/2022. R21HD091877 funded by the National Institute of Child Health and Human Development. Direct costs: \$324,090.
49. Multiple Principal Investigator (5-10% effort): ReCAPSE: Recurrence using Claims And PROs for SEER Expansion. 7/1/2020 – 12/31/2024 (Principal Investigators: Ruth Etzioni, Jessica Chubak, and Bin Huang). UH3CA218909 funded by the National Cancer Institute. Total direct costs: \$1,529,243. Kaiser Permanente Washington total direct costs: \$106,019.
50. Multiple Principal Investigator (22%-40% effort). Optimizing Colorectal Cancer Screening PREcision and Outcomes in CommuNity-baSEd Populations (PRECISE). 4/15/2018 – 3/31/2025 (Principal Investigators: Douglas Corley, Jessica Chubak, Aruna Kamineni, Joanne Schottinger, Ethan Halm, and Celette Skinner). UM1CA222035 funded by the National Cancer Institute. Total direct costs: \$13,875,933. Kaiser Permanente Washington direct costs: \$2,640,953.
51. Multiple Principal Investigator (10-20% effort). Multi-level Optimization of the Cervical Cancer Screening Process in Diverse Settings & Populations (METRICS). 4/10/2018 – 3/31/2025 (Principal Investigators: Jasmin Tiro, Aruna Kamineni/Jessica Chubak, Celette Skinner, and Jennifer Haas). UM1CA229140 funded by the National Cancer Institute. Total direct costs: \$12,605,491. Kaiser Permanente Washington direct costs: \$2,974,311. [Chubak replaced Kamineni as MPI in 2023].
52. Site Principal Investigator (6% effort). A case-control study to evaluate broad-spectrum antibiotic use and high birth weight as potential risk factors for early-onset colorectal cancer. 9/15/2021 – 8/30/2025. (Principal Investigator: Chun Chao). 1R01CA258160-01A1 funded by the National Cancer Institute. Kaiser Permanente Washington direct costs: \$63,611.
53. Co-investigator (5-10%). Cancer care experiences survey. 11/1/2023-12/31/2025. (Principal Investigator: Morgan Clennin). Funded by Kaiser Permanente. Kaiser Permanente Washington direct costs: \$529,304.

### **Currently funded projects**

1. Multiple Principal Investigator (10-15% effort). Leveraging machine learning to improve risk prediction for chemotherapy induced neuropathy. 6/1/2020 – 5/31/2026 (Principal Investigators: Alyce Adams, Jessica Chubak, Romain Neugebauer). R01CA249127-01 funded by the National Cancer Institute. Total direct costs: \$2,260,296. Kaiser Permanente Washington direct costs: \$392,524.
2. Multiple Principal Investigator (14%-25% effort). Clinical Care Gaps and Unmet Needs in Adolescent and Young Adult (AYA) Cancers. 9/15/2020 – 6/30/2026 (Principal Investigators: Lawrence H. Kushi, Jessica Chubak, Theresa H.M. Keegan, Erin Hahn, Hazel B. Nichols). P01CA233432-01A1 funded by the National Cancer Institute. Total direct costs: \$9,296,845. Kaiser Permanente Washington direct costs: \$1,382,722.
3. Co-investigator (20%). Biannual Cancer Care Experiences Survey. 1/1/2026 – 12/31/2026. (Principal Investigator: Larissa White). Funded by Kaiser Permanente. Kaiser Permanente Washington direct costs: \$316,009.

## PUBLICATIONS

<http://www.ncbi.nlm.nih.gov/sites/myncbi/jessica.chubak.1/bibliography/40881859/public/?sort=date&direction=ascending>

### Published peer-reviewed research articles

1. Tworoger SS, **Chubak J**, Aiello EJ, Ulrich CM, Atkinson C, Potter JD, Yasui Y, Stapleton PL, Lampe JW, Farin FM, Stanczyk FZ, McTiernan A. Association of *CYP17*, *CYP19*, *CYP11B1*, and *COMT* polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. *Cancer Epidemiol Biomarkers Prev*. 2004 Jan;13(1):94-101.
2. Tworoger SS, **Chubak J**, Aiello EJ, Yasui Y, Ulrich CM, Farin FM, Stapleton PL, Irwin ML, Potter JD, Schwartz RS, McTiernan A. The effect of CYP19 and COMT polymorphisms on exercise-induced fat loss in postmenopausal women. *Obes Res*. 2004 Jun;12(6):972-81.
3. McTiernan A, Tworoger SS, Rajan KB, Yasui Y, Sorenson B, Ulrich CM, **Chubak J**, Stanczyk FZ, Bowen D, Irwin ML, Rudolph RE, Potter JD, and Schwartz RS. Effect of exercise on serum androgens in postmenopausal women: A 12-Month randomized clinical trial. *Cancer Epidemiol Biomarkers Prev*. 2004 Jul;13(7):1099-1105.
4. **Chubak J**, Tworoger SS, Aiello EJ, Yasui Y, Ulrich CM, Stanczyk FZ, McTiernan A. Associations between reproductive and menstrual factors and postmenopausal sex hormone concentrations. *Cancer Epidemiol Biomarkers Prev*. 2004 Aug;13(8):1296-1301.
5. **Chubak J**, Tworoger SS, Yasui Y, Ulrich CM, Stanczyk FZ, McTiernan A. Associations between reproductive and menstrual factors and postmenopausal androgen concentrations. *Journal of Women's Health*. 2005 Nov;14(8):704-712.
6. Mohanka M, Heckbert SR, Yasui Y, Sorensen B, **Chubak J**, Tworoger SS, Ulrich CM, McTiernan A. Serum lipoproteins in overweight/obese postmenopausal women: 1-year exercise clinical trial. *Medicine & Science in Sports & Exercise*. 2006 Feb;38(2):231-9.
7. **Chubak J**, Ulrich CM, Tworoger SS, Sorensen B, Yasui Y, Irwin ML, Stanczyk FZ, Potter JD, McTiernan A. Effect of exercise on bone mineral density and lean mass in postmenopausal women. *Medicine & Science in Sports & Exercise*. 2006 Jul;38(7):1236-1244.
8. **Chubak J**, McTiernan A, Sorensen B, Wener MH, Yasui Y, Velasquez M, Wood B, Rajan KB, Wetmore CM, Potter JD, Ulrich CM. Moderate-intensity exercise reduces the incidence of colds among postmenopausal women – results from a randomized trial. *American Journal of Medicine*. 2006 Nov;119(11):937-942.
9. Tworoger S, Sorensen B, **Chubak J**, Irwin M, Stanczyk F, Ulrich C, Potter J, McTiernan A. Effect of a 12-month randomized clinical trial of exercise on serum prolactin concentrations in postmenopausal women. *Cancer Epidemiol Biomarkers Prev*. 2007 May;16(5):895-899.
10. Rhew I, Yasui Y, Sorensen B, Ulrich CM, Neuhouser M, Potter JD, Tworoger SS, **Chubak J**, Bowen DJ, McTiernan A. Minimal effects of an exercise intervention trial on self-reported health behaviors in obese post-menopausal women. *Contemporary Clinical Trials*. 2007 Jul;28(4):472-481.
11. **Chubak J**, Doherty JA, Cushing-Haugen KL, Voigt LF, Saltzman BS, Hill DA, Beresford SAA, Weiss NS. Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy. *Cancer Causes Control*. 2007 Nov;18(9):1001-1007.

12. **Chubak J**, Buist DSM, Boudreau DM, Rossing M, Lumley T, Weiss NS. Breast cancer recurrence risk in relation to antidepressant use after diagnosis. *Breast Cancer Research and Treatment*. 2008;112:123-132.
13. Hawkins V, Foster-Schubert K, **Chubak J**, Sorensen B, Ulrich CM, Stanczyk FZ, Plymate S, Stanford J, White E, Potter JD, McTiernan A. Effect of exercise on serum sex hormones in men: a 12-month randomized clinical trial. *Medicine & Science in Sports & Exercise*. 2008 Feb;40(2):223-233.
14. **Chubak J**, Bowles EA, Terry MB, Trentham-Dietz A, Buist DSM. Antidepressant medications and change in mammographic density in postmenopausal women. *Cancer Epidemiol Biomarkers Prev*. 2009 Feb;18(2):676-679.
15. **Chubak J**, Boudreau DM, Rulyak SJ, Mandelson MT. Colorectal cancer risk in relation to use of acid suppressive medications. *Pharmacoepidemiology and Drug Safety*. 2009 Jul;18(7):540-4.
16. Buist DSM, **Chubak J**, Prout M, Yood MU, Bosco JLF, Thwin SS, Gold HT, Owusu C, Field TS, Quinn VP, Wei F, Silliman RA. Referral, receipt, and completion of chemotherapy in patients with early-stage breast cancer older than 65 years and at high risk of breast cancer recurrence. *J Clin Oncol*. 2009 Aug;27(27):4508-4514.
17. **Chubak J**, Boudreau DM, Fishman PA, Elmore JG. Cost of breast-related care in the year following false positive screening mammograms. *Med Care*. 2010 Sep;48(9):815-20.
18. Green BB, Wang CY, Horner K, Catz S, Meenan RT, Vernon SW, Carrell D, **Chubak J**, Ko C, Laing S, Bogart A. Systems of Support to increase colorectal cancer screening and follow-up rates (SOS): design, challenges, and baseline characteristics of the study population. *Contemp Clin Trials*. 2010 Jul;31:589-603.
19. **Chubak J**, Boudreau DM, Rulyak SJ, Mandelson MT. Colorectal cancer risk in relation to antidepressant medication use. *Int J Cancer*. 2011 Jan;128(1):227-32.
20. \*Liss DT, **Chubak J**, Anderson ML, Saunders KW, Tuzzio L, Reid RJ. Patient-reported care coordination: associations with primary care continuity and specialty care use. *Ann Fam Med*. 2011 Jul-Aug;9(4):323-329.
21. **Chubak J**, Pocobelli G, Weiss NS. Tradeoffs between accuracy measures for electronic healthcare data algorithms for epidemiologic and health services research. *Journal of Clinical Epidemiology*. 2012 Mar;65(3):343-349.
22. **Chubak J**, Tuzzio L, Hsu C, Alfano CM, Rabin B, Hornbrook MC, Spegman A, Von Worley A, Williams A, Nehklyudov L. Providing care to cancer survivors in integrated healthcare delivery systems: practices, challenges, and research opportunities. *Journal of Oncology Practice*. 2012 May;8(3):184-9.
23. Bowles EJA, Buist DSM, **Chubak J**, Yu O, Johnson J, Chestnut J, Boudreau DM. Endocrine therapy initiation from 2001 through 2008 varies by age of breast cancer diagnosis and tumor size. *Journal of Oncology Practice*. 2012 Mar;8(2):113-120.
24. Green BB, Bogart A, **Chubak J**, Vernon SW, Morales LS, Meenan R, Laing SS, Fuller SF, Ko, C, Wang CY. Nonparticipation in a population-based trial to increase screening rates. *American Journal of Preventive Medicine*. 2012 Apr;42(4):390-7.
25. **Chubak J**, Yu O, Pocobelli G, Lamerato L, Webster J, Prout MN, Ulcickas Yood M, Barlow WE, Buist DSM. Algorithms to identify second breast cancer events using administrative data. *Journal of the National Cancer Institute*. 2012 Jun;104(12):931-40.

26. **Chubak J**, Anderson ML, Saunders KW, Hubbard RA, Tuzzio L, Liss DT, Morales LS, Reid RJ. Predictors of one-year change in patient activation among older adults with diabetes and heart disease. *Journal of the American Geriatrics Society*. 2012 Jul;60(7):1316-21.
27. Bowles EJA, Boudreau DM, **Chubak J**, Yu O, Fujii M, Chestnut J, Buist DSM. Patient-reported discontinuation of endocrine therapy and related side effects among women with early stage breast cancer. *Journal of Oncology Practice*. 2012 Nov;8(6):e149-57.
28. \*Pocobelli G, **Chubak J**, Hanson N, Drescher C, Resta R, Urban N, Buist DSM. Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counseling. *Gynecol Oncol*. 2012 Aug;126(2):229-35.
29. Henderson JA, **Chubak J**, O'Connell J, Ramos MC, Jensen J, Jobe, JB. Design of a randomized controlled trial of a web-based intervention to reduce cardiovascular disease risk factors among remote-dwelling American Indians. *J Prim Prev*. 2012 Aug;33(4):209-222.
30. Nekhlyudov L, Greene SM, **Chubak J**, Rabin B, Tuzzio L, Rolnick S, Field TS. Cancer Research Network: Using Integrated Healthcare Delivery Systems as Platforms for Cancer Survivorship Research. *Journal of Cancer Survivorship*. 2013 Mar;7(1):55-62.
31. Doubeni CA, Weimann S., Adams K, Kamineni A, Buist DM, Ash AS, Rutter CM, Doria-Rose VP, Corely DA, Greenlee RT, **Chubak J**, Williams A, Kross-Desrosiers AR, Johnson E, Webster J, Richert-Boe K, Levin TR, Fletcher RH, Weiss NS. Screening colonoscopy and risk of incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. *Annals of Internal Medicine*. 2013 Mar;158:312-320.
32. Green BB, Wang CY, Anderson ML, **Chubak J**, Meenan RT, Vernon SW, Fuller S. An automated intervention with stepped increases in support to increase uptake of colorectal cancer screening: a randomized trial. *Annals of Internal Medicine*. 2013 Mar;158(5 Pt 1):301-311.
33. **Chubak J**, Rutter CM, Kamineni A, Johnson EA, Stout NK, Weiss NS, Doria-Rose VP, Doubeni CA, Buist DSM. Measurement in comparative effectiveness research. *American Journal of Preventive Medicine*. 2013 May;44(5):513-519.
34. \*Lowry S, **Chubak J**, Press OW, McKnight B, Weiss NS. Risk of non-Hodgkin lymphoma in relation to tricyclic antidepressant use. *Annals of Epidemiology*. 2013 Jun;23(6):349-354.
35. Perdue D, **Chubak J**, Dillard D, Bogart A, Buchwald D. A comparison of colorectal cancer screening uptake among average-risk insured American Indian/Alaska Native and white women. *Journal of Health Care for the Poor and Underserved*. 2013 Aug;24(3):1125-35.
36. Wirtz HS, Buist DSM, Gralow JR, Barlow WE, Gray SL, **Chubak J**, Yu O, Bowles EJA, Fujii M, Boudreau DM. Frequent antibiotic use and second breast cancer events. *Cancer Epidemiol Biomarkers Prev*. 2013 Sep;22(9):1588-99.
37. **Chubak J**, Boudreau DM, Wirtz HS, McKnight B, Weiss NS. Threats to the validity of non-randomized studies of post-diagnosis exposures on cancer recurrence and survival. *Journal of the National Cancer Institute*. 2013 Oct;105(19):1456-62.
38. **Chubak J**, Bogart A, Fuller S, Laing SS, Green BB. Uptake and positive predictive value of fecal occult blood tests: a randomized controlled trial. *Prev Med*. 2013 Nov;57(5):671-8.
39. Wagner E, Aiello Bowles EJ, **Chubak J**, Horner K, Lapham B, Ludman E, McCorkle R, Penfold R, Reid F, Rutter C. Nurse navigators in early cancer care: a randomized, controlled trial. *Journal of Clinical Oncology*. 2014 Jan;32(1):12-8.

40. Laing SS, Bogart A, **Chubak J**, Fuller S, Green BB. Psychological distress after a positive fecal occult blood test result among members of an integrated delivery system. *Cancer Epidemiol Biomarkers Prev. Cancer Epidemiol Biomarkers Prev.* 2014 Jan;32(1):154-9.
41. Carrell D, Halgrim S, Tran D-T, Buist DSM, **Chubak J**, Chapman WW, Savova GK. Using natural language processing to improve efficiency of manual chart abstraction in research: the case of breast cancer recurrence. *American Journal of Epidemiology.* 2014 Mar;179(6):749-58.
42. Boudreau DM, Yu O, **Chubak J**, Wirtz HS, Bowles EJA, Fujii M, Buist DSM. Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. *Breast Cancer Res Treat.* 2014 Apr;144(2):405-16.
43. **Chubak J**, Aiello Bowles EJ, Tuzzio L, Ludman E, Rutter CM, Reid RJ, Wagner E. Perspectives of cancer survivors on the role of different healthcare providers in an integrated delivery system. *Journal of Cancer Survivorship: Research and Practice.* 2014 Jun;8(2):229-38.
44. Tiro JA, Kamineni A, Levin TR, Zheng Y, Schottinger JC, Rutter CM, Corley DA, Skinner CS, **Chubak J**, Doubeni CA, Halm E, Gupta S, Wernli K, Klabunde CK. The colorectal cancer (CRC) screening process in community settings: A conceptual model for the Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) Consortium. *Cancer Epidemiol Biomarkers Prev.* 2014 Jul;23(7):1147-58.
45. Wernli KJ, Hubbard R, Johnson E, **Chubak J**, Kamineni A, Green BB, Rutter CM. Patterns of colorectal cancer screening uptake in newly-eligible men and women. *Cancer Epidemiol Biomarkers Prev.* 2014 Jul;23(7):1230-7.
46. Wang CY, Tapsoba JD, Anderson M, Vernon SW, **Chubak J**, Fuller S, Green B. Time to Screening in the Systems of Support to Increase Colorectal Cancer Screening Trial. *Cancer Epidemiol Biomarkers Prev.* 2014 Aug;23(8):1683-8.
47. Murphy CC, Vernon SW, Haddock NM, Anderson ML, **Chubak J**, Green BB. Longitudinal predictors of colorectal cancer screening among participants in a randomized controlled trial. *Preventive Medicine.* 2014 Sep;66:123-30.
48. Andersen MR, Thorpe J, Buist DSM, Beatty JD, Watabayashi K, Hanson N, Resta R, **Chubak J**, Urban N. Cancer risk awareness and concern among women with a family history of breast or ovarian cancer. *Behavioral Medicine.* 2014 Jul;25:1-11.
49. Green BB, Wang CY, Vernon SW, **Chubak J**, Meenan RT, Fuller S. Results of nurse navigator follow-up after positive colorectal cancer screening test: a randomized trial. *Journal of the American Board of Family Medicine.* 2014 Nov-Dec;27(6):789-795.
50. Hubbard RA, **Chubak J**, Rutter CM. Estimating screening test utilization using electronic health records data. *eGEMs (Generating Evidence & Methods to improve patient outcomes).* 2014 Vol. 2: Iss. 1, Article 14.
51. **Chubak J**, Hubbard RA, Johnson E, Kamineni A, Rutter CM. Assessing the effectiveness of a screening test for cancer in the presence of another screening modality in nonrandomized studies. *Journal of Medical Screening.* 2015;22(2):69-75.
52. **Chubak J**, Onega T, Zhu W, Buist DSM, Hubbard RA. An electronic health record-based algorithm to ascertain the date of second breast cancer events. *Medical Care.* 2017 Dec; 55(12):e81-e87. [Epub 2015 Apr 10].

53. Meenan RT, Anderson ML, **Chubak J**, Vernon SW, Fuller S, Wang C-Y, Green BB. An economic evaluation of colorectal cancer screening in primary care practice. *American Journal of Preventive Medicine*. 2015 June;48(6):714-721
54. Ludman EJ, McCorkle R, Bowles EA, Rutter CM, **Chubak J**, Tuzzio L, Jones S, Reid RJ, Penfold R, Wagner EH. Do depressed newly diagnosed cancer patients differentially benefit from nurse navigation? *General Hospital Psychiatry*. 2015 May-Jun;37(3):236-9.
55. Adams KF, Johnson EA, **Chubak J**, Kamineni A, Doubeni CA, Buist DSM, Williams AE, Weinmann S, Doria-Rose VP, Rutter CM. Development of an algorithm to classify colonoscopy indication from coded care plan data. *eGEMS (Generating Evidence & Methods to improve patient outcomes)*. 2015 Vol 3: Iss. 1, Article 11.
56. Green BB, Anderson ML, **Chubak J**, Fuller S, Meenan RT, Vernon SW. Impact of continued mailed fecal tests in the patient-centered medical home: year 3 of the Systems of Support to Increase Colorectal Screening and Follow-up randomized trial. *Cancer*. 2016 Jan;122:321-21.
57. **Chubak J**, Bowles EJA, Yu O, Buist DSM, Fujii M, Boudreau DM. Breast cancer recurrence in relation in antidepressant use. *Cancer Causes & Control*. 2016 Jan;27:125-36.
58. Jones SMW, Ziebell R, Walker R, Nekhlyudov L, Rabin BA, Nutt S, Fujii M, **Chubak J**. Psychometric investigation of benefit finding among long-term cancer survivors using the Medical Expenditure Panel Survey. *European Journal of Oncology Nursing*. 2016 Feb;20:31-5.
59. **Chubak J**, Garcia MP, Burnett-Hartman A, Zheng Y, Corley DA, Halm EA, Singal AG, Klabunde CN, Doubeni CA, Kamineni A, Levin TR, Schottinger JE, Green BB, Quinn VP, Rutter CM. Time to colonoscopy after positive fecal blood test in four U.S. healthcare systems. *Cancer Epidemiology, Biomarkers & Prevention*. 2016 Feb;25(2):344-50.
60. Kroenke CH, **Chubak J**, Johnson L, Castillo A, Weltzien E, Caan BJ. Enhancing the utility of breast cancer recurrence algorithms through selective use of medical record data. *Journal of the National Cancer Institute*. 2016 Mar;108(3).
61. Hubbard RA, Ripping TM, **Chubak J**, Broeders MJM, Miglioretti DL. Statistical methods for estimating the cumulative risk of screening mammography outcomes. *Cancer Epidemiology, Biomarkers & Prevention*. 2016 Mar;25(3):513-20.
62. Hubbard RA, Johnson E, **Chubak J**, Wernli K, Kamineni A, Bogart A, Rutter CM. Accounting for misclassification in electronic health records-derived exposures using generalized linear finite mixture models. *Health Services and Outcomes Research Methodology*. 2017 Jun;17(2):101-112. [Epub 2016 June 3].
63. **Chubak J**, Whitlock EP, Williams SB, Kamineni A, Burda BU, Buist DSM, Anderson ML. Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force. *Annals of Internal Medicine*. 2016 Jun 21;164(12):814-25.
64. **Chubak J** and Hawkes R. Animal-assisted activities in pediatric oncology: results from a survey of top-ranked pediatric oncology hospitals. *Journal of Pediatric Oncology Nursing*. 2016 Jul;33(4):289-96.
65. Green BB, Anderson ML, **Chubak J**, Vernon SW, LM Baldwin, Tuzzio L, Catz S, Cole A. Impact of patient centered medical home implementation on colorectal cancer screening rates in year 1 of the Systems of Support to Increase Colorectal Cancer Screening trial. *Journal of the Board of Family Medicine*. 2016 Mar-Apr;29(2):191-200.

66. Drescher CW, Beatty D, Resta R, Andersen MR, Watabayashi K, Thorpe J, Purkey H, **Chubak J**, Hanson N, Buist DSM, Urban N. Systematic identification of high risk women for genetic counseling and surgical prevention of ovarian cancer. *Cancer*. 2016 Jul 22. doi: 10.1002/cncr.30190. [Epub ahead of print].
67. Klabunde CN, Zheng Y, Quinn VP, Beaber EF, Rutter CM, Halm EA, **Chubak J**, Doubeni CA, Haas JS, Kamineni A, Schapira M, Vacek PM, Garcia MP, Corley DA. Influence of age and comorbidity on completion of colorectal cancer screening in the elderly. *American Journal of Preventive Medicine*. 2016 Sep;51(3):e67-75.
68. Shortreed SM, Johnson EJ, Rutter CM, Kamineni A, **Chubak J**. Cohort restriction based on prior enrollment: examining potential biases in estimating cancer risk. *Observational Studies*. 2016 Sept;2:51-64.
69. Burnett-Hartman AN, Mehta SJ, Zheng Y, Ghai NR, McLerran D, **Chubak J**, Quinn VP, Skinner CS, Corley DA, Inadomi J, Doubeni CA on behalf of the PROSPR Consortium. Racial/Ethnic Disparities in Colorectal Cancer Screening Across Healthcare Systems. *American Journal of Preventive Medicine*. 2016 Oct;51(4):e107-15.
70. McCarthy AM, Kim JJ, Beaber EF, Zheng Y, Burnett-Harman A, **Chubak J**, Ghai NR, McLerran D, Breen N, Conant EF, Geller BM, Green BB, Klabunde C, Inrig S, Skinner CS, Quinn VP, Haas JS, Schnall M, Rutter CM, Barlow WE, Corley DA, Armstrong K, Doubeni CA, on behalf of the PROSPR consortium. Timely follow-up of abnormal breast and colorectal cancer screening tests in women by race/ethnicity. *American Journal of Preventive Medicine*. 2016 Oct;51(4):507-12.
71. Halm EA, Beaber EF, McLerran D, **Chubak J**, Corley DA, Rutter CM, Doubeni CA, Haas JS, Balasubramanian BA. Association between primary care visits and colorectal cancer screening outcomes in the era of population health outreach. *Journal of General Internal Medicine*. 2016 Oct;31(10):1190-7.
72. **Chubak J**, Ziebell R, Greenlee RT, Honda S, Hornbrook MC, Epstein M, Nekhlyudov L, Pawloski PA, Ritzwoller DP, Ghai NR, Feigelson HS, Clancy HA, Doria-Rose VP, Kushi LH. The Cancer Research Network: a platform for epidemiologic and health research on cancer prevention, care, and outcomes in large, stable populations. *Cancer Causes & Control*. 2016 Nov;27(11):1315-1323.
73. Singal AG, Tiro J, Li X, Adams-Huet B, **Chubak J**. Factors associated with hepatocellular carcinoma surveillance rates among patients with cirrhosis in a population-based integrated healthcare delivery system. *Journal of the Clinical Gastroenterology*. 2017 Aug;51(7):650-655. [Epub 2016 Nov 18].
74. Nekhlyudov L, Walker R, Ziebell R, Rabin B, Nutt S, **Chubak J**. Cancer survivors' experiences with insurance, finances, and employment: results from a multi-site study. *Journal of Cancer Survivorship: Research and Practice*. 2016 Dec;10(6):1104-1111.
75. **Chubak J** and Hubbard RA. Defining and measuring adherence to cancer screening guidelines. *Journal of Medical Screening*. 2016 Dec;23(4):179-185.
76. Jones SMW, Ziebell R, Walker R, Nekhlyudov L, Rabin BA, Nutt S, Fujii M, **Chubak J**. Association of worry about cancer and benefit-finding among long-term survivors of cancer. *Supportive Care in Cancer*. 2017 May;25(5):1417-1422. [Epub 2016 Dec 15].
77. Hardikar S, Burnett-Hartman AN, **Chubak J**, Upton MP, Zhu L, Potter JD, Newcomb PA. Reproductive factors and risk of colorectal polyps in a colonoscopy based study in western Washington State. *Cancer Causes & Control*. 2017 Feb 15;28(3):241-246.[Epub 2017 Feb 15.]

78. **Chubak J**, Hawkes R, Dudzik C, Foose-Foster JM, Eaton L, Johnson RH, Macpherson CF. Pilot study of therapy dog visits for inpatient youth with cancer. *Journal of Pediatric Oncology Nursing*. 2017 Sept/Oct; 34:331-41. [Epub 2017 Jun 14].
79. Reed SC, Walker R, Ziebell R, Rabin B, Nutt S, **Chubak J**, Nekhlyudov L. Cancer survivors' reported discussions with health care providers about follow-up care and receipt of written care plans. *Journal of Cancer Education*. 2017 May 8. doi: 10.1007/s13187-017-1228-1. [Epub ahead of print].
80. Green BB, Anderson ML, Cook AJ, **Chubak J**, Fuller S, Meenan RT, Vernon SW. A centralized mailed program with stepped increases of support increases time in compliance with colorectal cancer screening guidelines over 5 years: a randomized trial. *Cancer*. 2017 Nov 15;123(22):4472-4480. [Epub 2017 July 28].
81. Chen L, **Chubak J**, Boudreau DM, Barlow WE, Weiss NS, Li CI. Use of antihypertensive medications and risk of adverse breast cancer outcomes in a SEER-Medicare population. *Cancer Epidemiology, Biomarkers & Prevention*. 2017 Nov;26(11):1603-1610. [Epub 2017 Aug 14.]
82. Chen L, **Chubak J**, Boudreau DM, Barlow WE, Weiss NS, Li CI. Diabetes treatment and risks of adverse breast cancer outcomes among elderly breast cancer patients: A SEER-Medicare analysis. *Cancer Research*. 2017 Nov 1;77(21):6033-6041. [Epub 2017 Sep 21].
83. Singal AG, Corley DA, Kamineni A, Garcia M, Zheng Y, Doria-Rose VP, Quinn VP, Jensen CD, **Chubak J**, Tiro J, Doubeni CA, Ghai NR, Skinner CS, Wernli K, Halm EA. Patterns and predictors of repeat fecal occult blood test screening in four large health systems in the United States. *American Journal of Gastroenterology*. 2018 May;113(5):746-754. [Epub 2018 Feb 27.]
84. Jones SMW, Walker R, Fujii M, Nekhlyudov L, Rabin BA, **Chubak J**. Financial difficulty, worry about affording care, and benefit finding in long-term survivors of cancer. *Psycho-Oncology*. 2018 Apr;27(4):1320-1326. doi: 10.1002/pon.4677. [Epub 2018 Mar 8.]
85. Selby K, Jensen CD, Lee JK, Doubeni CA, Schottinger JE, Zhao WK, **Chubak J**, Halm E, Ghai NR, Contreras R, Skinner C, Kamineni A, Levin TR, Corley DA. Influence of varying quantitative fecal immunochemical test positivity thresholds on colorectal cancer detection: a community-based cohort study. *Annals of Internal Medicine*. 2018 Oct 2;169(7):439-447. doi 10.7326/M18-0244. [Epub 2018 Sept 18].
86. **Chubak J**, Yu O, Ziebell RA, Bowles EJ, Sterrett AT, Fujii MM, Boggs JM, Burnett-Hartman AN, Boudreau DM, Chen L, Floyd JS, Ritzwoller DP, and Hubbard RA. Risk of colon cancer recurrence in relation to diabetes. *Cancer Causes & Control*. 2018 Nov;29(11):1093-1103. [Epub 2018 Sep 22].
87. Chen Y, Wang J, **Chubak J**, Hubbard RA. Inflation of the type I error rate due to differential misclassification in EHR-derived outcomes: Empirical illustration using breast cancer recurrence. *Pharmacoepidemiology and Drug Safety*. 2019 Feb;28(2):264-268 [Epub 2018 Oct 30].
88. **Chubak J**, McLerran D, Zheng Y, Singal AG, Corley DA, Doria-Rose VP, Doubeni CA, Kamineni A, Haas JS, Halm EA, Skinner CS, Zauber AG, Wernli KJ, Beaber EF. Receipt of colonoscopy following high risk findings: an analysis of four integrated healthcare delivery systems. *Cancer Epidemiology, Biomarkers & Prevention*. 2019 Jan;28(1):91-98. doi: 10.1158/1055-9965.EPI-18-0452. [Epub 2018 Nov 20].
89. Kamineni A, Tiro JA, Beaber EF, Silverberg M, Wheeler CM, Chao CR, **Chubak J**, Kim J, Balasubramanian B, Corley DA, Skinner CS, Thornquist M, Quinn V, Doria-Rose VP. Cervical cancer screening research in the PROSPR I Consortium: rationale, methods, and baseline findings

from a US cohort. *International Journal of Cancer*. 2019 Mar 15;144(6):1460-1473. doi: 10.1002/ijc.31940. [Epub 2018 Dec 20].

90. Mayer SE, Weiss NS, **Chubak J**, Doody DR, Carlson CS, Makar KW, Wurscher MA, Malone KE. CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy. *Cancer Causes & Control*. 2019 Jan;30(1):103-112. doi: 10.1007/s10552-018-1117-x. [Epub 2018 Dec 12].
91. Pocobelli G, Yu O, Ziebell R, Bowles EA, Fujii M, Sterrett A, Boggs J, Chen L, Boudreau D, Hubbard R, **Chubak J**. Use of antidepressants after colon cancer diagnosis and risk of recurrence. *Psycho-Oncology*. 2019 Apr;28(4):750-758. doi: 10.1002/pon.5015. [Epub 2019 Jan 31]
92. Bowles EJA, Anderson ML, Crane PK, **Chubak J**, LaCroix AZ, Walker RL, Keene CD, Rosenberg D, Crane PK, Larson EB. Resilience to neuropathology changes in the human brain. *Journal of Alzheimer's Disease*. 2019;68(3):1071-1083. doi: 10.3233/JAD-180942. [Epub 2019 Mar 18]
93. Bowles EJA, Yu O, Ziebell R, Chen L, Boudreau DM, Ritzwoller DP, Hubbard RA, Boggs JM, Burnett-Hartman AN, Sterrett A, Fujii M, **Chubak J**. Cardiovascular medication use and risks of colon cancer recurrences and additional cancer events: a cohort study. *BMC Cancer*. 2019 Mar 27;19(1):270. doi: 10.1186/s12885-019-5493-8. [Epub 2019 Mar 27]
94. Boudreau DM, Chen L, Yu O, Bowles EJA, **Chubak J**. Risk of second breast cancer events with chronic opioid use in breast cancer survivors. *Pharmacoepidemiol Drug Saf*. 2019 May;28:740-753. doi: 10.1002/pds.4779. [Epub 2019 April 3]
95. Clarke CL, Kushi LH, **Chubak J**, Pawloski PA, Bulkley JE, Epstein MM, Burnett-Hartman AN, Powell B, Pearce CL, Feigelson H. Predictors of long-term survival among high-grade serous ovarian cancer patients. *Cancer Epidemiology, Biomarkers, and Prevention*. 2019 May;28(5):996-999. doi: 10.1158/1055-9965.EPI-18-1324. [Epub 2019 Apr 9.]
96. Breen N, Skinner CS, Zheng Y, Inrig S, Corley DA, Beaber EF, Garcia MP, **Chubak J**, Doubeni C, Quinn VP, Haas JS, Li C, Wernli KJ, Klabunde CN, PROSPR Consortium. Time to follow-up after colorectal cancer screening by health insurance type. *American Journal of Preventive Medicine*. 2019 May;56(5):e143-e152. doi: 10.1016/j.amepre.2019.01.005. [Epub 2019 April 16]
97. Haas CB, Phipps AI, Hajat A, **Chubak J**, Wernli KJ. Time to fecal immunochemical test completion for colorectal cancer screening. *American Journal of Managed Care*. 2019 Apr;25(4):174-180.
98. Burnett-Hartman, AN, Powers D, **Chubak J**, Corley DA, Ghai NR, McMullen CK, Pawloski PA, Sterrett AT, Feigelson HS. Treatment patterns and survival difference between early-onset and late-onset colorectal cancer patients: the Patient Outcomes to Advance Learning Network. *Cancer Causes & Control*. 2019 Jul;30(7):747-755. doi: 10.1007/s10552-019-01181-3. [Epub 2019 May 17]
99. Green BB, Anderson ML, Cook AJ, **Chubak J**, Fuller S, Kimbel KJ, Kullgren JT, Meenan RJ, Vernon SW. Financial incentives to increase colorectal cancer screening uptake and decrease disparities: a randomized clinical trial. *JAMA Netw Open*:(7)2;2019 .e196570. doi:10.1001/jamanetworkopen.2019.6570. [Epub 2019 July 5]
100. Pocobelli G, Ziebell R, Fujii M, Hutcheson KA, Chang S, McClure JB, **Chubak J**. Symptom burden in long-term survivors of head and neck cancer: patient-reported versus clinical data. *eGEMs (Generating Evidence & Methods to improve patient outcomes)* 2019 July;7(1): 25:1–10. doi: <https://doi.org/10.5334/egems.271>. [Epub 2019 July 10]
101. Burnett-Hartman AN, **Chubak J**, Hua X, Ziebell R, Kamineni A, Zhu L, Upton MP, Hardikar S, Newcomb PA. The association between colorectal sessile serrated adenomas/polyps and subsequent

advanced colorectal neoplasia. *Cancer Causes and Control*. 2019 Sep; 30(9): 979–987. [Epub 2019 July 9]

102. Barlow WE, Beaber EF, Geller BM, Kamineni A, Zheng Y, Haas JS, Chao CR, Rutter CM, Zauber AG, Sprague BL, Halm EA, Weaver DL, **Chubak J**, Doria-Rose VP, Kobrin S, Onega T, Quinn VP, Schapira MM, Tosteson ANA, Corley DA, Skinner CS, Schnall MD, Armstrong K, Wheeler CM, Silverberg MJ, Balasubramanian BA, Doubeni CA, McLerran D, Tiro JA on behalf of the PROSPR consortium. Evaluating screening participation, follow-up and outcomes for breast, cervical and colorectal cancer in the PROSPR consortium. *J Natl Cancer Inst*. 2020 Mar 1;112(3):238-246. doi: 10.1093/jnci/djz137. [Epub 2019 Jul 11].
103. Burnett-Hartman AN, Kamineni A, Corley DA, Singal AG, Halm EA, Rutter CM, **Chubak J**, Lee JK, Doubeni CA, Inadomi JM, Doria-Rose VP, Zheng Y. Colonoscopy Indication Algorithm Performance Across Diverse Health Care Systems in the PROSPR Consortium. *EGEMS (Wash DC)*. 2019 Aug 2;7(1):37. doi: 10.5334/egems.296.
104. Check DK, Hutcheson KA, Poisson L, Pocobelli G, Sakoda LC, Zaveri J, Chang SS, **Chubak J**. Factors associated with employment discontinuation among older and working age survivors of oropharyngeal cancer. Accepted (8/15/2019): *Head and Neck*. 2019 Nov;41(11):3948-3959. doi: 10.1002/hed.25943. [Epub 2019 Sep 6]
105. Tong J, Huang J, **Chubak J**, Wang X, Hubbard RA, Chen Y. An augmented estimation procedure for EHR-based association studies accounting for differential misclassification. 2020 Feb 1;27(2):244-253. doi: 10.1093/jamia/ocz180. [Epub before print]
106. Lee JK, Jensen CD, Levin TR, Zauber AG, **Chubak J**, Kamineni A, Schottinger JE, Ghai NR, Udaltsova N, Zhao WK, Fireman BH, Quesenberry CP, Oray J, Skinner SK, Halm EA, Corley DA. Long-term risk of colorectal cancer and related deaths after adenoma removal in a large, community-based population. 2020 Mar;158(4):884-894.e5. doi: 10.1053/j.gastro.2019.09.039. [Epub 2019 Oct 4]
107. Chen L, **Chubak J**, Yu O, Pocobelli G, Ziebell RA, Bowles EJA, Fujii MM, Sterrett AT, Boggs JM, Ritzwoller DP, Hubbard RA, Boudreau DM. Changes in use of opioid therapy after colon cancer diagnosis: a population-based study. *Cancer Causes & Control*. 2019 Dec;30(12):1341-1350. doi: 10.1007/s10552-019-01236-5. [Epub 2019 Oct 30]
108. Reding KW, Aragaki AK, Cheng RK, Barac A, Wassertheil-Smoller S, **Chubak J**, Limacher MC, Hundley WG, D'Agostino Jr R, Vitolins MZ, Brasky TM, Habel LA, Chow EJ, Jackson RD, Chen C, Morgenroth A, Barrington WE, Banegas M, Barnhart M, and Chlebowski RT. Cardiovascular outcomes in relation to anti-hypertensive medication use in women with and without cancer: Results from the Women's Health Initiative. *The Oncologist*. 2020 Apr 6. doi: 10.1634/theoncologist.2019-0977. [Epub ahead of print]
109. Zheng Y, Corley DA, Doubeni C, Halm E, Shortreed SM, Barlow WE, Zauber A, Tosteson TD, **Chubak J**. Analyses of preventive care measures with incomplete historical data in electronic medical records: An example from colorectal cancer. *Annals of Applied Statistics*. 2020;14(2):1030-1044.
110. Hua X, Newcomb PA, **Chubak J**, Malen R, Ziebell R, Kamineni A, Zhu LC, Upton MP, Wurscher MA, Thomas SS, Newman H, Hardikar S, Burnett-Hartman AN. Association of colorectal serrated polyp molecular characteristics associated with subsequent advanced neoplasia. *Cancer Causes and Control*. 2020 Jul;31(7):631-640. doi: 10.1007/s10552-020-01304-1. [Epub 2020 May 1]

111. **Chubak J**, Anderson ML, Cook AJ, Murphy CC, Jackson ML, Green BB. Methodological considerations in calculating and analyzing proportion of time covered as a measure of longitudinal cancer screening adherence. *Cancer Epidemiology, Biomarkers & Prevention*. 2020 Aug;29(8):1549-1556. doi: 10.1158/1055-9965.EPI-20-0388. [Epub 2020 May 28]
112. Ghai NG, Jensen CD, Merchant SA, Schottinger JE, Lee JK, **Chubak J**, Kamineni AS, Halm E, Skinner CS, Haas JS, Cannizzaro N, Schneider JL, Corley DA. Primary care provider beliefs and recommendations about colorectal cancer screening in four healthcare systems. *Cancer Prevention Research*. 2020 Nov;13(11):947-958. doi: 10.1158/1940-6207.CAPR-20-0109. [Epub 2020 Jul 15]
113. A'mar T†, Beatty JD, Fedorenko C, Markowitz D, Corey T, Lange J, Schwartz SM, Huang B, **Chubak J**†, Etzioni R†. Incorporating breast cancer recurrence events into population-based cancer registries using medical claims. *JMIR Cancer*. 2020 Jul-Dec;6(2):e18143.
114. Hubbard RA, Lett E, Ho GYF, **Chubak J**. Characterizing bias due to differential exposure ascertainment in electronic health record data. *Health Services and Outcomes Research Methodology*. *Health Serv Outcomes Res Method*. 2021 Sep;21(3):309-323. doi:10.1007/s10742-020-00235-3. [Epub 2021 Jan 4]
115. Beatty JD, Sun Q, Markowitz D, **Chubak J**, Huang B, Etzioni R. Identifying breast cancer recurrence histories via patient-reported outcomes. *Journal of Cancer Survivorship*. 2022 Apr;16(2):388-396. doi: 10.1007/s11764-021-01033-7. [Epub 2021 Apr 14]
116. Green BB, Anderson ML, Cook AJ, **Chubak J**, Fuller S, Meenan RT, Vernon SW. A centralized mailed program with stepped support increases time in compliance with colorectal cancer screening over 9 years: a randomized trial. *Journal of General Internal Medicine*. 2022 Apr;37(5):1073-1080. doi: 10.1007/s11606-021-06922-2. [Epub 2021 May 29]
117. Zhu Y, Hubbard RA, **Chubak J**, Roy J, Mitra N. Core concepts in pharmacoepidemiology: Violations of the positivity assumption in the causal analysis of observational data: consequences and statistical approaches. *Pharmacoepidemiology and Drug Safety*. 2021 Nov;30(11):1471-1485. doi: 10.1002/pds.5338. [Epub 2021 Aug 24]
118. Haas JS, Cheung D, Yu L, Atlas SJ, Clark, C, Silver MI, Feldman S, Kamineni A, Tiro JA, **Chubak J**, Pocobelli G, Kobrin SC. Variation in receipt of Human Papilloma Virus (HPV) co-testing for cervical cancer screening: patient, provider, facility and healthcare system characteristics. *Prev Med*. 2022 Jan;154:106871. doi: 10.1016/j.ypmed.2021.106871. [Epub 2021 Nov 8]
119. Liu XL, **Chubak J**, Hubbard RA, Chen Y. SAT: a Surrogate Assisted Two-wave case boosting sampling method, with application to EHR-based association studies. *Journal of the American Medical Informatics Association*. 2022 Apr;29(5):918-927. doi: 10.1093/jamia/ocab267. [Epub 2021 Dec 28]
120. Nichols HB, Wernli KJ, Chawla N, O'Meara ES, Figueroa Gray M, Green LE, Anderson C, Baggett CD, Casperson M, Chao C, Jones SMW, Kirchhoff AC, Kuo T-M, Lee C, Malogolowkin M, Quesenberry CP, Ruddy KJ, Wun T, Zebrack B, **Chubak J**†, Hahn EH†, Keegan THM†, Kushi LH. † Challenges and opportunities of epidemiological studies to reduce the burden of cancers in young adults. *Current Epidemiology Reports*. 2023;10(3):115–124. doi: 10.1007/s40471-022-00286-9. [Epub 2022 Mar 29]
121. Pocobelli G, Ichikawa L, Yu O, Green BB, Meyers K, Gray R, Shea M, **Chubak J**. Validation of International Classification of Disease, Tenth Revision, Clinical Modification Diagnosis Codes for Heart Failure Subtypes. *Pharmacoepidemiology and Drug Safety*. 2022 Sep;31(9):992-997. doi: 10.1002/pds.5489. [Epub 2022 Jun 7]

122. Schottinger JE, Jensen CD, Ghai NR, **Chubak J**, Lee JK, Kamineni A, Halm EA, Sugg-Skinner C, Udaltsova N, Zhao WK, Ziebell RA, Contreras R, Kim EJ, Fireman B, Quesenberry CP, Corley DA. Association of physician adenoma detection rates with postcolonoscopy colorectal cancer. *JAMA*. 2022 Jun;327(21):2114-2122. [Epub 2022 Jun 7]
123. Nicholson BD, Thompson MJ, Hobbs FDR, Nguyen M, McLellan J, Green BB, **Chubak J**, Oke JL. Measured weight loss as a precursor to cancer diagnosis: a retrospective cohort study of 43,032 primary care patients. *Journal of Cachexia, Sarcopenia and Muscle*. 2022 Oct;13: 2492–2503. doi: 10.1002/jcsm.13051. [Epub 2022 Jul 28]
124. **Chubak J**, Burnett-Hartman AN, Barlow WE, Corley DA, Croswell JM, Neslund-Dudas C, Vachani A, Silver MI, Tiro JA, Kamineni A. Estimating cancer screening sensitivity and specificity using healthcare utilization data. *Cancer Epidemiology, Biomarkers, and Prevention*. 2022 Aug;31(8):1517-1520. doi: 10.1158/1055-9965.EPI-22-0232. [Epub 2022 Aug 2]
125. Beaber EF, Kamineni A, Burnett-Hartman AN, Hixon B, Kobrin S, Li CI, Oliver M, Rendle KA, Skinner CS, Todd K, Zheng Y, Ziebell R, Breslau ES, **Chubak J**, Corley DA, Greenlee RT, Haas JS, Halm EA, Honda S, Neslund-Dudas C, Ritzwoller DP, Schottinger JE, Tiro JA, Vachani A, Doria-Rose VP. Evaluating and improving cancer screening process quality in a multilevel context: the PROSPR II consortium design and research agenda. *Cancer Epidemiology, Biomarkers, and Prevention*. 2022 Aug;31(8):1521-1531. doi: 10.1158/1055-9965.EPI-22-0100. [Epub 2022 Aug 2]
126. **Chubak J**, Dalmat RR, Weiss NS, Doria-Rose VP, Corley DA, Kamineni A. Informative presence in electronic health record data: a challenge in implementing study exclusion criteria. *Epidemiology*. 2023 Jan;34(1):29-32. doi: 10.1097/EDE.0000000000001542. [Epub 2022 Sep 16]
127. Sarma EA, Thompson JM, Bowles EA, Burnett-Hartman AN, Chen L, Hubbard RA, Yu O, **Chubak J**. Patient and tumour characteristics of screening-age adults diagnosed with screen-detected versus symptomatic colon cancer: *Colorectal Dis*. 2022 Nov;24(11):1344-1351. doi: 10.1111/codi.16232. [Epub 2022 Jun 23]
128. Kamineni A, Doria-Rose VP, **Chubak J**, Inadomi JM, Corley DA, Haas JS, Kobrin SC, Winer RL, Elston Lafata J, Beaber EF, Yudkin JS, Zheng Y, Skinner CS, Schottinger JE, Ritzwoller DP, Croswell JM, and Burnett-Hartman AN. Evaluation of harms reporting in United States cancer screening guidelines. *Annals of Internal Medicine*. 2022 Nov;175(11):1582-1590. doi: 10.7326/M22-1139. [Epub 2022 Sep 27]
129. Chao C, **Chubak J**, Beaber EF, Kamineni A, Mao C, Silverberg MJ, Tiro JA, Skinner C, Garcia M, Corley DA, Winer RL, Raine-Bennett T, Feldman S, Wheeler CM. Gaps in the screening process for women diagnosed with cervical cancer in five diverse US health care settings. *Cancer Medicine*. 2023 Feb;12(3):3705-3717. doi: 10.1002/cam4.5226. [Epub 2022 Sep 15]
130. \*Dalmat R, Ziebell RA, Kamineni A, Phipps AI, Weiss NS, Breslau ES, Corley DA, Green BB, Halm EA, Levin TR, Schottinger JE, **Chubak J**. Risk of colorectal cancer and colorectal cancer mortality beginning ten years after a negative colonoscopy, among screen-eligible adults 76-85 years old. *Cancer Epidemiology, Biomarkers, and Prevention*. 2023 Jan;32(1):37-45. doi: 10.1158/1055-9965.EPI-22-0581. [Epub 2022 Sep 13]
131. **Chubak J**, Pocobelli G, Adler A, Ziebell R, Hawkes R, Bobb J, and Zerr D. Effects of the COVID-19 pandemic on animal-assisted activities in pediatric hospitals. 2022 Sep 30:S0891-5245(22)00281-4. doi: 10.1016/j.pedhc.2022.09.011. [Epub 2022 Sep 30]

132. Feldman S, Lykken JM, Haas JS, Werner CL, Kobrin SC, Tiro JA, **Chubak J**, Kamineni A. Factors associated with timely colposcopy following an abnormal cervical cancer test result. *Prev Med*. 2022 Nov;164:107307:107307. doi: 10.1016/j.ypmed.2022.107307. [Epub 2022 Oct 18]
133. Del Vecchio NJ, Beaber E, Garcia MP, Wheeler CM, Kamineni A, Chao C, **Chubak J**, Corley DA, Owens CL, Winer RL, Pruitt SL, Raine-Bennett T, Feldman S, and Silverberg M. Provider- and facility-level variation in cervical biopsy diagnoses. *Journal of Lower Genital Tract Disease*. 2023 Apr 1;27(2):113-119. doi: 10.1097/LGT.0000000000000721. [Epub 2023 Jan 17]
134. Selby K, Sedki M, Levine E, Kamineni A, Green BB, Vachani A, Haas JS, Ritzwoller DP, Croswell JM, Ohikere K, Doria-Rose VP, Rendle KA, **Chubak J**, Elston Lafata J, Inadomi J, Corley DA. Test performance metrics for breast, cervical, colon, and lung cancer screening: a systematic review. *J Natl Cancer Inst*. 2023 Apr 11;115(4):375-384. doi: 10.1093/jnci/djad028. [Epub 2023 Feb 8]
135. Corley DA, Jensen CD, **Chubak J**, Schottinger JE, Halm EA, Udaltsova N; PROSPR PRECISE Consortium. Evaluating different approaches for calculating adenoma detection rate: is screening colonoscopy the gold standard?" *Gastroenterology*. 2023 Sep;165(3):784-787.e4. doi: 10.1053/j.gastro.2023.05.025. [Epub 2023 May 30.]
136. McCarthy AM, Tiro JA, Hu E, Ehsan S, **Chubak J**, Kamineni A, Feldman S, Atlas SJ, Silver MI, Kobrin S, and Haas JS. Factors associated shorter-interval cervical cancer screening for young women. *Preventive Medicine*. *Prev Med Rep*. 2023 Jun 11;35:10227. <https://doi.org/10.1016/j.pmedr.2023.102279>. [Epub 2023 Jun 14]
137. \*Dalmat RR, Ziebell RA, Kamineni A, Phipps AI, Weiss NS, Breslau ES, Burnett-Hartman AN, Corley DA, Doria-Rose VP, Green BB, Halm EA, Levin TR, Schottinger JE, **Chubak J**. Risk of colorectal cancer and colorectal cancer mortality beginning one year after a negative fecal occult blood test, among screen-eligible adults 76-85 years old. *Cancer Epidemiol Biomarkers Prev*. 2023 Oct 2;32(10):1382-1390. doi: 10.1158/1055-9965.EPI-23-0265. Online ahead of print.
138. Alimena S, Lykken JM, Tiro JA, **Chubak J**, Kamineni A, Haas JS, Werner SC, Feldman S. Timing of colposcopy and risk of cervical cancer. *Obstet Gynecol*. *Obstet Gynecol*. 2023 Nov 1;142(5):1125-1134. doi: 10.1097/AOG.0000000000005313. [Epub 2023 Aug 22]
139. **Chubak J**, Adler A, Bobb JF, Hawkes RJ, Ziebell RA, Pocobelli G, Ludman EJ, Zerr DA. A randomized controlled trial of animal assisted activities for pediatric oncology patients: psychosocial and microbial outcomes. *Journal of the Pediatric Infectious Diseases Society*. 2023 Nov 4:S0891-5245(23)00279-1. doi: 10.1016/j.pedhc.2023.09.010. Online ahead of print.
140. Rasouli B, **Chubak J**, Floyd JS, Psaty BM, Nguyen M, Walker RL, Wiggins KL, Logan RW, Danaei G. Combining high-quality data with rigorous methods: emulating a target trial using electronic medical records and a case-control design. *BMJ* 2023;383:e072346. [Epub 12/28/2023]
141. Bowles EJA, Kroenke CH, **Chubak J**, Bhimani J, O'Connell K, Brandzel S, Valice E, Doud R, Theis MK, Roh JM, Heon N, Peraud S, Griggs JJ, Bandera EV, Kushi LH, Kantor ED. Evaluation of algorithms using automated health plan data to identify breast cancer recurrences. *Cancer Epidemiol Biomarkers Prev*. 2024 Mar 1;33(3):355-364. doi: 10.1158/1055-9965.EPI-23-0782. [Epub 2023 Dec 13]
142. Abrahão R, Brunson A, **Chubak J**, Wernli KJ, Nichols HB, Chao C, Ruddy KJ, Hahn EE, Li Q, Malogolowkin MH, Sauder CAM, Kushi LH, Wun T, Keegan, THM. Late Venous Thromboembolism in Survivors of Adolescent and Young Adult Cancer: A Population-Based Study

- in California. *Thrombosis Research*. 2024 Mar;235:1-7. doi: 10.1016/j.thromres.2024.01.002. [Epub 2024 Jan 15]
143. White LL, Burnett-Hartman AN, Ichikawa LE, Goldberg SR, **Chubak J**, Feigelson HS, Kamineni A. SARS-CoV-2 infection and related hospitalization among cancer survivors. *Cancer Epidemiol Biomarkers Prev*. 2024 Mar 1;33(3):442-444. doi: 10.1158/1055-9965.EPI-23-1303. [Epub 2023 Dec 21]
144. Abrahão R, Brunson A, Li Q, Li J, Ruddy KJ, Ryder MM, **Chubak J**, Nichols HB, Sauder CAM, Figueroa Gray M, Hahn EE, Wun T, Keegan THM. Late endocrine diseases in survivors of adolescent and young adult cancer in California: A population-based report from the VOICE Study. *Br J Cancer*. 2024 Apr;130(7):1166-1175. doi: 10.1038/s41416-024-02594-x. [Epub 2024 Feb 8]
145. Lee JK, Roy A, Jensen CD, Chan JT, Zhao W, Levin TR, **Chubak J**, Halm E, Sugg Skinner C, Schottinger JE, Ghai RH, Burnett-Hartman A, Kamineni R, Udaltsova N, Corley DA. Surveillance colonoscopy findings in older adults with a history of colorectal adenomas. *JAMA Netw Open*. 2024 Apr 1;7(4):e244611. doi: 10.1001/jamanetworkopen.2024.4611.
146. Lee JK, Jensen CD, Udaltsova N, Zheng Y, Levin TR, **Chubak J**, Kamineni A, Halm EA, Skinner CS, Schottinger JE, Ghai NR, Burnett-Hartman A, Issaka R, Corley DA. Predicting risk of colorectal cancer after adenoma removal in a large, community-based setting. *American Journal of Gastroenterology*. 2024 Aug 1;119(8):1590-1599. [Epub 2024 Feb 14]
147. Wernli KJ, Haupt EC, Chawla N, Osuji TA, Shen E, Smitherman AB, Casperson M, Kirchhoff A, Zebrack BJ, Keegan TMH, Kushi L, Baggett C, Kaddas HK, Ruddy KJ, Sauder CAM, Wun T, Figueroa Gray M, Chubak J, Nichol HB, Hahn EE. Emergency department use in adolescent and young adult (AYA) cancer early survivors from 2006 to 2020. *Journal of Adolescent and Young Adult Oncology*. 2024;13(5):738-747. doi: 10.1089/jayao.2023.0174. [Epub 2024 Apr 29]
148. Hahn EE, Munoz-Plaza CE, Ghai N, Pak K, Amundsen BI, Contreras R, Cannizzaro N, Levin TR, Jensen CD, **Chubak J**, Green BB, Skinner CS, Halm EA, Schottinger J. Patterns of care following positive fecal blood test results for colorectal cancer screening: a mixed-methods study. *Journal of General Internal Medicine*. 2024 Dec;39(16):3205-3216. doi: 10.1007/s11606-024-08764-0. [Epub 2024 May 21]
149. Issaka RB, Ibekwe LN, Todd KW, Burnett-Hartman AN, Clark CR, Del Vecchio NJ, Kamineni A, Neslund-Dudas C, **Chubak J**, Corley DA, Haas JS, Honda SA, Li CI, Winer RL, Pruitt SL. Association between racial residential segregation and screening uptake for colorectal and cervical cancer among Black and White patients in five U.S. healthcare systems. *Cancer*. 2024 Dec 15;130(24):4287-4297. doi: 10.1002/cncr.35514. [Epub 2024 Aug 9]
150. Lu Y, Tong J, **Chubak J**, Lumley T, Hubbard RA, Xu H, Chen Y. Leveraging error-prone algorithm-derived phenotypes: enhancing association studies for risk factors in EHR data. *Journal of Biomedical Informatics*. 2024 Jul 14;157:104690. doi: 10.1016/j.jbi.2024.104690. [Epub 2024 Jul 14]
151. Dang TH, Rieu-Werden, Kobrin SC, Tiro JA, Lykken JM, **Chubak J**, Atlas SJ, Higashi RT, Lee SC, Haas JS, Skinner CS, Silver MI, Feldman S. Association between clinician confidence and making guideline-recommended decisions in the management of abnormal cervical cancer screening results. *J Gen Intern Med*. 2024 Dec;39(16):3217-3224. doi: 10.1007/s11606-024-08943-z. [Epub 2024 Jul 25]
152. Figueroa Gray MS, Shapiro L, Dorsey CN, Randall S, Casperson M, Chawla N, Zebrack B, Fujii MM, Hahn EE, Keegan THM, Kirchhoff AC, Kushi LH, Nichols HB, Wernli KJ, Sauder CAM,

- Chubak J.** A patient-centered conceptual model of AYA cancer survivorship care. *Cancers*. 2024;16(17):3073; <https://doi.org/10.3390/cancers16173073>. [Epub 4 Sept 2024]
153. Alimena S, Lykken JM, Tiro JA, **Chubak J**, Haas JS, Werner C, Kobrin SC, Silver MI, Perkins RB, Feldman S. Accessibility of criteria to exit cervical cancer screening at age 65 years in the electronic health record. *O&G Open* 1(3):p 032, September 2024. doi: 10.1097/og9.0000000000000035. [Epub 19 Sept 2024]
154. Harlass M, Dalmat R, **Chubak J**, Van den Puttelaar R, Udaltsova N, Corley DA, Jensen CD, Collier N, Ozik J, Landsorp-Vogelaar I, Meester R. Stopping ages for colorectal cancer screening based on sex, comorbidity, and screening history. *JAMA Network Open*. 2024 Dec 2;7(12):e2451715. doi: 10.1001/jamanetworkopen.2024.51715. [Epub 19 Dec 2024]
155. **Chubak J**, Ichikawa LE, Merchant SA, Dalmat RR, Ziebell RA, Jensen CD, Lee JK, Corley DA, Ghai NR, Green BB, Skinner CS, Schottinger JE, Breslau ES, Levin TR. Incidence of serious complications following screening colonoscopy in adults aged 76 to 85 years old. *Cancer Epidemiol Biomarkers Prev*. 2025 Feb 6;34(2):281-289. doi: 10.1158/1055-9965.EPI-24-0551. [Epub 2024 Nov 25]
156. Tiro JA, Lykken J, Chen P, Clark CR, Kobrin S, **Chubak J**, Feldman S, Werner C, Atlas S, Silver MI, Haas J. Delivering guideline-concordant care for patients with high-risk HPV and normal cytologic findings. *JAMA Network Open*. 2025 Jan 2;8(1):e2454969. doi: 10.1001/jamanetworkopen.2024.54969. [Epub 17 Jan 2025]
157. Lee JK, Jensen CD, Merchant SA, Chubak J, Halm EA, Corley DA. Adverse events following surveillance colonoscopy in older adults across four large health systems in the United States. *Clinical Gastroenterology and Hepatology*. 2025 Nov;23(12):2348-2351.e2. doi: 10.1016/j.cgh.2025.03.028. [Epub 2025 May 27]
158. Clark CR, Lykken JM, Chen PM, Haas JS, Feldman S, Ahn C, Gu CA, Kobrin S, Silver MI, Atlas SJ, **Chubak J**, Tiro JA. Barriers to the equitable implementation of risk-based cervical cancer management guidelines. *Journal of General Internal Medicine*. doi:10.1007/s11606-025-09611-6. [Epub 30 May 2025]
159. Hahn EE, Haupt EC, Chawla N, Osuji T, Shen E, Smitherman AB, Casperson M, Kirchoff AC, Zebrack BJ, Laurent C, Keegan THM, Abrahão R, Ruddy KJ, **Chubak J**, Nichols H, Wernli KJ. Transitions within and use of primary and oncology care in survivors of adolescent and young adult-onset cancers. *JCO Oncol Pract*. 2025 Jun 20:OP2400886. doi: 10.1200/OP-24-00886. [Epub 20 Jun 2025]
160. Abrahão R, Ruddy KJ, Laurent CA, **Chubak J**, Haupt EC, Brunson AM, Hahn EE, Chao CR, Moy LM, Wun T, Kushi LH, Keegan THM, Sauder CAM. Trastuzumab therapy and new-onset hypertension in adolescents and young adults with breast cancer. *Breast Cancer Research and Treatment*. 2025 Aug;213(1):81-92. doi: 10.1007/s10549-025-07760-0. [Epub 27 June 2025]
161. Pocobelli G, Lykken JM, Haas JS, Tiro JA, Doria-Rose VP, Hyun N, Silver MI, Kamineni A, **Chubak J**. Positive predictive value of cervical cancer screening results recommended for colposcopy by human papillomavirus vaccination status at 3 U.S. healthcare systems. *Cancer Causes and Control*. 2025 Nov;36(11):1549-1561. doi: 10.1007/s10552-025-02039-7. [Epub 2025 Aug 6]
162. Haas JS, Todd KW, McLerran D, Tiro JA, Vachani A, Kobrin S, Saia C, Skinner CS, Zheng Y, **Chubak J**, Corley DA, Greenlee RT, Halm EA, Li CI. Gaps in care delivery across the cancer screening continuum for cervical, colorectal and lung cancer. *JNCI*. 2025 Sep 10:djaf248. doi: 10.1093/jnci/djaf248. Online ahead of print.

163. Halm EA, Vecchio NJ, Rendle KA, Tiro JA, Zheng Y, Winer RL, Haas JS, Corley DA, Skinner CS, Schottinger J, Ghai NR, **Chubak J**. Longitudinal adherence to screening for colorectal, cervical, and lung cancer in a US consortium. *Journal of General Internal Medicine*. 2025 Oct 7. doi: 10.1007/s11606-025-09835-6. Online ahead of print.
164. De Jonge L, Lansdorp-Vogelaar I, Doria-Rose VP, Portillo I, Novak Mlakar D, Buron A, Quintin C, Espinàs JA, Plaine J, Škrjanec AL, Kofol Bric T, Binefa G, Font Marimon R, Bulliard JL, **Chubak J**, Ziebell R, McCurdy BR, Rabeneck LM, Senore C. Global impact of COVID-19 on organized CRC screening programs: lessons learned. *Best Practices & Research Clinical Gastroenterology*. 5 Sep 2025. doi:10.1016/j.bpg.2025.102047. Online ahead of print.
165. Keegan T, Abrahão R, **Chubak J**, Sauder C, Ruddy K, Quesenberry C, Li Q, Haupt E, Laurent C, Brunson A, Casperson M, Chao C, Smitherman A, Nichols H, Kirchhoff A, Kushi L, Hahn E. Incidence of chronic medical conditions among survivors of adolescent and young adult cancer compared to a population without cancer. *Cancer*. 2025 Oct 15;131(20):e70125. doi: 10.1002/cncr.70125. Online ahead of print.
166. Parker K, Heneghan MB, Li QW, Brunson A, Ou J, Kaddas HK, Abrahão R, **Chubak J**, Wernli KJ, Zebrack B, Hahn EE, Kushi LH, Nichols HB, Keegan T, Kirchhoff AC. Identifying clustering in patterns of late effects among survivors of adolescent and young adult Hodgkin lymphoma. *JNCI Spectrum*. 2025 Oct 1:pkaf094. doi: 10.1093/jncics/pkaf094. Online ahead of print.
167. Brunson A, Wun T, Abrahão R, Quesenberry C, **Chubak J**, Ruddy KJ, Chao C, Hahn EE, Sauder CAM, Nichols HB, Kushi L, Keegan THM. Metastatic recurrence among adolescents and young adults with cancer in California: A population-based study. *JAMA Oncol*. 2025 Nov 26. doi: 10.1001/jamaoncol.2025.4971. Online ahead of print.
168. Ou JY, Keegan K, Li QW, Kaddas HK, Abrahão R, Brunson A, Sauer C, **Chubak J**, Kushi L, Hahn E, Chao C, Nichols H, Kirchhoff AC. Identifying patterns of late effects with latent class analysis among adolescent and young adult thyroid cancer survivors in California and Utah. *Cancer Med*. 2025 Dec;14(23):e71316. doi: 10.1002/cam4.71316.
169. Jones SMW, Keegan THM, Hahn EE, Nichols B, O'Meara ES, Figueroa Gray M, Wernli KJ, Sauder CAM, Kirchhoff AC, Laurent CA, Moy L, Kushi LH, **Chubak J**. Test-retest reliability and mode effects on single item and multi-item measures in a survey of adolescent and young adults with cancer. *Journal of Adolescent and Young Adult Oncology*. 2026 Jan 12. <https://doi.org/10.1177/21565333251414792>. Online ahead of print.
170. Chao CR, Xu L, Wu BU, Figueiredo JC, Getahun D, Cannavale KL, Gilfillan A, **Chubak J**. Revision under review: Association between broad-spectrum antibiotic use and risk of early-onset colorectal cancer. *Cancer Epidemiol Biomarkers Prev*. 2026 Jan 13. doi: 10.1158/1055-9965.EPI-25-0912. Online ahead of print.

\*Denotes mentee

†Authors contributed equally

### Other peer-reviewed scholarly publications

1. **Chubak J**. What can epidemiology contribute to comparative effectiveness research (CER)? *Journal of Epidemiology & Community Health*. 2013;67(3):206-207.
2. **Chubak J**, Yu O, Buist SM, Wirtz HS, Boudreau DM. Time Scales in Epidemiologic Follow-up Studies: Extending Considerations to Studies of Disease Prognosis. *Epidemiology*. 2013;24(4):628-9.

3. Danaei G, Rasouli B, **Chubak J**, Floyd JS, Psaty BM, Nguyen M, Walker R, Wiggins K, Logan RW, Dickerman BA, Hernán MA. Developing New Methods for Comparing Treatments in Case-Control Studies. Patient-Centered Outcomes Research Institute (PCORI). 2021. <https://doi.org/10.25302/07.2021.ME.160936748>

### Book chapters and published reviews

1. **Chubak J**, Kamineni A, Buist DS, Anderson ML, Whitlock EP. Aspirin Use for the Prevention of Colorectal Cancer: An Updated Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 133. AHRQ Publication No. 15-05228-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2015.
2. Hubbard RA, Harton J, Zhu W, Wang L, **Chubak J**. 2017. Methods for time to event analyses using imperfect electronic health records-derived endpoints. In: *New Advances in Statistics and Data Science*. Springer.

### Other non-peer-reviewed scholarly publications

1. Robey T, Benki S, Mitchell B, Roberts M, **Chubak J**, FOSEP- A Model Student-led Group Linking Science and Society. *Journal of the Federation of American Scientists*. 2005 Winter:13-14.
2. Ulrich CM, **Chubak J**, McTiernan A. Re: Exercise, vitamins and respiratory tract infections. *American Journal of Medicine*. 2007 Dec;120(12):e19.
3. Hudson SV, **Chubak J**, Coups EJ, Blake-Gumbs L, Jacobsen PB, Neugut AI, Buist DSM. Identifying key questions to advance research and practice in cancer survivorship follow-up care: a report from the ASPO survivorship interest group. *Cancer Epidemiol Biomarkers Prev*. 2009 Jul;18(7):2152-4.
4. Hamilton JG, Birmingham WS, Tehranifar P, Irwin ML, Klein WMP, Nebling L, **Chubak J**. Transitioning to independence and maintaining a career in the new funding climate: a report from the American Society of Preventive Oncology's Junior Members Interest Group. *Cancer Epidemiol Biomarkers Prev*. 2013 Nov;22(11):2138-42.
5. Carrell D, Halgrim S, Tran D-T, Buist DSM, **Chubak J**, Chapman WW, Savova GK. Carrell et al. Respond to "Observational Research and the EHR." *American Journal of Epidemiology*. 2014 Mar;179(6):762-3.
6. **Chubak J**, Hawkes R, Dudzik C, Ziebell RA, Sherman KJ. "The choice of control conditions in animal-assisted intervention research." *Integrative Cancer Therapies*. 2021; 20:1-2. [Epub 24 Jun 2021]
7. **Chubak J** and Lund J. Noncancer comparators in cancer survivorship studies. *Cancer*. 2022 Aug;128(15):2994. [Epub 2022 May 3]
8. **Chubak, J**. "Developing an Intuition for Collider Restriction Bias." *OSF Preprints*. doi:10.31219/osf.io/hn25f. [Epub 2022 July 7]

### Non-author contributions (group authorship)

1. Beaver EF, Kim JJ, Schapira MM, Tosteson AN, Zauber AG, Geiger AM, Kamineni A, Weaver DL, Tiro JA; Population-based Research Optimizing Screening through Personalized Regimens Consortium. Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening. *J Natl Cancer Inst*. 2015 May 7;107(6):d120. doi: 10.1093/jnci/d120. Print 2015 Jun.

### Published abstracts

1. Lowry S, **Chubak J**, McKnight B, Press O, Weiss N. Risk of Non-Hodgkin Lymphoma in Relation to Tricyclic Antidepressant Use. *Cancer Epidemiology Biomarkers & Prevention* 2012;OF8-OF9.
2. **Chubak J**, Boudreau DM, Buist DSM, McKnight B, Rossing MA, Weiss NS. Approaches to reducing confounding by indication in a study of breast cancer prognosis in relation to the use of antidepressants after diagnosis. *Pharmacoepidemiology and Drug Safety* 2006; 15:S94-S.
3. Boudreau D, **Chubak J**, Stang P, Wirtz H, Key D, Von Korff M. Comparison of Different Methods for Calculating Medication Exposure. *Pharmacoepidemiology and Drug Safety* 2011; 20:S309-S.
4. **Chubak J**, Tuzzio L, Hsu C, Alfano C, Rabin B, Hornbrook M, Spegman A, Von Worley A, Williams A, Nekhlyudov L. Providing Care to Cancer Survivors in Integrated Health Care Delivery Systems: Barriers, Facilitators and Opportunities. *Psycho-Oncology* 2013; 22:2-3.
5. **Chubak J**, Hubbard RA, Johnson E, Kamineni A, Rutter CM. Assessing the effectiveness of a cancer screening test in the presence of another screening modality in nonrandomized studies. *American Journal of Epidemiology* 2013; 177:S110-S.
6. Boudreau DM, Yu OC, **Chubak J**, Bowles E, Wirtz HS, Fujii M, et al. Comparative Safety of Cardiovascular Medication Use and Breast Cancer Outcomes. *Pharmacoepidemiology and Drug Safety* 2013; 22:192-.
7. Wirtz HS, Buist DSM, Gralow JR, Barlow WE, Gray S, **Chubak J**, Yu O, Bowles E, Fujii M, Boudreau DM. Frequent Antibiotic Use and Breast Cancer Outcomes. *Pharmacoepidemiology and Drug Safety* 2013; 22:73-.
8. Ludman E, Bowles E, Rutter C, **Chubak J**, Penfold R, Reid R, et al. Newly Diagnosed Cancer Patients With and Without Depressive Symptoms Benefit From Nurse Navigation. *Psycho-Oncology* 2014; 23:109-10.
9. Nekhlyudov L, Walker R, Ziebell R, Rabin B, Nutt S, **Chubak J**. Cancer survivors' experiences with insurance, employment and personal finances: Results from a multi-site study. *Journal of Clinical Oncology* 2015; 33:1.
10. Resta R, Drescher CW, Beatty D, Andersen MR, Watabayashi K, Thorpe J, Purkey H, **Chubak J**, Hanson N, Buist DSM, Urban N. Systematic identification of high risk women for genetic counseling and surgical prevention of ovarian cancer. *Clinical Cancer Research* 2015; 21:1.
11. Dickerson JF, **Chubak J**, Rabin B, Nekhlyudov L, Varga AM, Fujii M, Ziebell R, Banegas MP. The association between employment changes and healthcare use in the year after cancer diagnosis. *Journal of Clinical Oncology* 2017; 35:5.
12. Jones S, Ziebell R, Walker R, Nekhlyudov L, Rabin B, Nutt S, Fujii M, **Chubak J**. Relationship of worry about cancer to perceived risk and positive and negative effects of cancer. *Ann Behav Med* 2017; 51:S1897-S8.
13. Chao C, Xu L, **Chubak J**, Figuerado JC, Getahun D, Cannavale KL, Gilfillan A, Wu BE. Broad-spectrum antibiotic use and risk of early-onset colorectal cancer. Annual Meeting, American Society of Clinical Oncology, 2024. *J Clin Oncol* 42, 2024 (suppl 16; abstr e15653).
14. Rathod R, Hu E, Pruitt S, Tiro JA, **Chubak J**, Haas J, Atlas SJ, Kruse G, Hughes AE. Association of multi-level factors with cervical cancer screening in healthcare settings [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; *Cancer Res* 2024;84(6\_Suppl):Abstract nr 3451.

15. Harlass M, Dalmat RR, **Chubak J**, van den Puttelaar R, Udaltsova N, Corley DA, Jensen CD, Collier N, Ozik J, Lansdorp Vogelaar, Meester R. 910 Modeling optimal stop ages for colorectal cancer screening based on sex, comorbidity, and screening history. *Gastroenterology*. 2024;166(5):S-220 - S-221.
16. Abrahão R., Smitherman A., Sauder C., Ruddy K., Nichols H., Chubak J., Kirchoff A., Kushi L., Hahn E., Keegan T. Incidence of chronic medical conditions in adolescent and young adult survivors of hematologic malignancies in California, 2006–2020. EACR25-1701. *Molecular Oncology*. 2025; 19(Suppl. 1):581-582.

### Submitted manuscripts under review

1. Pruitt SL, Xiong D, Hughes AE, Haas JS, Cheng D, **Chubak J**, Kamineni A, Clark C, Skinner CS, Kim E, Yang S. Multiple levels of influence on cervical cancer screening in four healthcare settings. Revision invited: *CEBP*.
2. Zheng Y, Kamineni A, Beaber EF, **Chubak J**, Corley DA, Doria-Rose VP, Tiro JA, Vachani A, Barlow WE, Burnett-Hartman AN, Elston Lafata JE, Green BB, Haas JC, Li CI, Selby K, Croswell JM. Measuring effective, safe, timely, efficient, equitable, and patient-centered cancer screening quality measures. Under review: *Journal of Primary Care and Community Health*.
3. **Chubak J**, Ichikawa L, Ziebell RA, Udaltsova N, Corley DA, Ghai NR, Lee JK, Halm EA, Skinner CS, Quesenberry C, Schottinger JE, Levin TR. Positive predictive value of symptoms for early-onset colorectal cancer and advanced neoplasia. Revision under review: *Cancer Epidemiol Biomarkers Prev*.
4. Oshiro CE, Cushing-Haugen KL, Del Vecchio NJ, Alonge OD, Ghai NR, Green BB, Honda SA, Neslund-Dudas C, Ritzwoller DP, Skinner CS, Tao M, Vachani A, **Chubak J**, Corley DA, Haas JS, Li CI, Tiro JA, Rendle KA. Body mass index and initiation of cancer screening: a closer look at differences by race, ethnicity, and sex in a multi-center population. Under review: *American Journal of Preventive Medicine*.
5. Halm EA, Nair R, Skinner CS, Hu E, Lykken JM, Green B, Jensen CD, Levin TR, Schottinger J, Ghai NR, Corley DA, **Chubak J**. Longitudinal adherence with fecal immunochemical testing for colorectal cancer: screening in four US health systems. Under review: *Clinical Gastroenterology and Hepatology*.
6. Pocobelli G, Del Vecchio NJ, Cushing-Haugen K, Kamineni A, Corley DA, Rendle KA, Halm EA, Li CI, Carroll NM, Oshiro CE, Silver MI, Greenlee RT, Neslund-Dudas C, Breslau ES, **Chubak J**. Screening up-to-date status as of recommended ages for discontinuation of routine colorectal, cervical, and lung cancer screening. Revision under review: *JNCI*.
7. Mukherjee A, Xu L, Getahun D, **Chubak J**, Figueiredo JC, Cannavale KL, Gilfillan AD, Wu BU, Chao CR. Association of high birth weight with risk of early-onset colorectal cancer. Revision under review: *Cancer Epidemiol Biomarkers Prev*.
8. Del Vecchio NJ, Chubak J, Rendle KA, Halm EA, Zheng Y, Winer RL, Silver MI, Corley DA, Greenlee RT, Carroll NM, Haas JS, Li CI, Neslund-Dudas C, Schottinger J, Burnett-Hartman AN. Prior screening patterns among lung and colorectal cancer patients and associations with stage at diagnosis. Revision under review: *Cancer Epidemiol Biomarkers Prev*.

## PRESENTATION OF RESEARCH FINDINGS AT PROFESSIONAL MEETINGS

### Contributed oral presentations

1. “Human germline genetic modification and our responsibilities to future generations.” New Zealand Bioethics Conference. Dunedin, New Zealand, 2002.
2. “A student initiated grassroots effort to increase dialogue about science.” American Association for the Advancement of Science. St. Louis, Missouri, 2006.
3. “Endometrial cancer risk in former users of unopposed estrogens: The influence of switching to combined estrogen-progestin therapy.” Congress of Epidemiology. Seattle, Washington, 2006.
4. “Breast cancer recurrence risk in relation to antidepressant use after diagnosis” HMO Research Network Annual Meeting. Minneapolis, Minnesota, 2008.
5. “Colorectal cancer risk in relation to antidepressant use.” American Society of Preventive Oncology. Tampa, Florida, 2009. *Honored as one of the top 16 abstracts submitted.*
6. “Providing care for cancer survivors in integrated delivery systems: preliminary results from an assessment of current practices and future opportunities.” HMO Research Network Annual Meeting. Austin, Texas, 2010.
7. “Algorithms to identify second breast cancer events from administrative data.” Society for Epidemiologic Research Annual Meeting. Minneapolis, Minnesota, 2012.
8. “Assessing the effectiveness of a cancer screening test in the presence of another screening modality.” Society for Epidemiologic Research Annual Meeting. Boston, Massachusetts, 2013.
9. “The Cancer Research Network: a platform for survivorship research.” Biennial Cancer Survivorship Research Conference. Atlanta, Georgia, 2014.

### Invited oral presentations

1. “Methodological challenges in comparing the effectiveness of approaches to cancer screening.” Western North American Region of the International Biometric Society. Seattle, Washington, 2010.
2. “Introduction to the Chronic Care Model.” Cancer Survivorship & Chronic Care Roundtable, George Washington Cancer Institute. Washington DC, 2011.
3. “Common ground: proposed terminology for consistency in comparative effectiveness research—the case of cancer screening.” American Society of Preventive Oncology. Washington DC, 2012.
4. “Providing Care to Cancer Survivors in Integrated Health Care Delivery Systems: Barriers, Facilitators, and Opportunities.” American Psychosocial Oncology Society 10th Annual Conference. Huntington Beach, California, 2013.
5. “Commonly used medications and risk of colorectal cancer recurrence.” National Cancer Institute, Division of Cancer Control and Prevention, New Grantee Workshop, Rockville, Maryland, 2014.
6. “Data Improvement in the Cancer Research Network.” HMO Research Network Conference. Phoenix, Arizona, 2014.
7. “Research careers within health care systems.” Professional development session on “International/alternative career paths.” Epidemiology Congress of the Americas, Miami, Florida, 2016.

8. “EMR algorithms for health research: what, when, and how?” Health Care Systems Research Network Conference. San Diego, California, 2017.
9. “Using claims and electronic health record data to study cancer screening: challenges and opportunities.” Society for Epidemiologic Research. Baltimore, Maryland, 2018.
10. “Using health care data to study and improve colorectal cancer screening.” 3<sup>rd</sup> Seattle Symposium on Health Care Data Analytics. Seattle, Washington, 2018.
11. “Recurring challenges in studying cancer recurrence.” UNC Lineberger Cancer Outcomes Research Program Breakfast Seminar. Chapel Hill, North Carolina, 2019.
12. “Administrative and EHR data: What, why, and how?” 7<sup>th</sup> Kolokotronis Symposium on Data Science, Harvard University, Boston, Massachusetts, 2019.
13. “Methodological issues in observational studies of second-line diabetes agents.” 7<sup>th</sup> Kolokotronis Symposium on Data Science, Harvard University, Boston, Massachusetts, 2019.
14. “Using electronic health care data to study cancer screening: challenges and opportunities.” NCI Cancer Prevention and Control Colloquia Series, National Cancer Institute, 2020.
15. Invited panelist. “Collaboration in Data Science: How Biostatisticians and Epidemiologists Contribute to the Creation of Real World Evidence — Topic Contributed Panel”. Joint Statistical Meeting (JSM). Virtual, 2020.
16. Invited panelist. “Design considerations for reducing measurement error in cancer research using real-world data” in “Research Using EHR Data Across the Cancer Continuum: Bias, Governance, Linkages.” American Society of Preventive Oncology. Tucson, Arizona, 2022.
17. “Screening as Practiced: Results from the PRECISE Study.” Co-presented with Rebecca Ziebell. CISNET-Colon Working Group, Mid-Year Meeting. Seattle, Washington, 2023.
18. “End-user recommendations for advancing registry-based cancer research.” National Academies of Science, Engineering and Medicine. Enabling 21st Century Applications for Cancer Surveillance through Enhanced Registries and Beyond. Washington DC and virtual. 2024.

### Meeting presentations made by preceptees

1. Lowry S. “Risk of non-Hodgkin lymphoma in relation to tricyclic antidepressant use.” American Society of Preventive Oncology. Washington DC, 2012. *Honored as one of the top 20 abstracts submitted.*
2. Lowry S. “Risk of non-Hodgkin lymphoma in relation to tricyclic antidepressant use.” American College of Epidemiology. Chicago, Illinois, 2012. *Received Doctoral Student Prize.*

### Poster presentations

1. Tworoger SS, **Chubak J**, Aiello EJ, Ulrich CM, Yasui Y, Janssen P, Potter J, Farin F, McTiernan A, “Association between *CYP17*, *CYP19*, and *COMT* genotypes and estrogen and SHBG concentrations in postmenopausal women.” American Association for Cancer Research. Washington DC, 2003.
2. Mitchell B, Roberts M, Benki S, **Chubak J**, Robey T. “The Forum on Science Ethics and Policy: A new Seattle organization stimulates discussion on the role of science in our society.” American Association for the Advancement of Science. Washington DC, 2005.
3. **Chubak J**, Tworoger SS, Yasui Y, Ulrich CM, Stanczyk FZ, McTiernan A. “Associations between reproductive and menstrual factors and postmenopausal androgen concentrations.” American Association for Cancer Research. Anaheim, California, 2005.

4. Tworoger SS, Sorensen B, **Chubak J**, McTiernan A. “The effect of a 12-month randomized controlled trial of exercise on serum prolactin concentrations in postmenopausal women.” Congress of Epidemiology. Seattle, Washington, 2006.
5. Hawkins V, **Chubak J**, Sorensen B, Stanford J, White E, McTiernan A. “Influence of exercise on serum sex hormones in men: a 12-month randomized controlled clinical trial.” Congress of Epidemiology. Seattle, Washington, 2006.
6. **Chubak J**, Buist DSM, Boudreau DM, McKnight B, Rossing MA, Weiss NS. “Approaches to reducing confounding by indication in a study of breast cancer prognosis in relation to the use of antidepressants after diagnosis.” International Congress of Pharmacoepidemiology. Lisbon, Portugal, 2006.
7. Tuzzio L, **Chubak J**, Hsu C, Kirlin B, Nekhlyudov L, for the CRN Survivorship Scientific Interest Group. “Providing care for cancer survivors in integrated delivery systems: an assessment of current practices and future opportunities.” AcademyHealth. Boston, Massachusetts, 2010.
8. **Chubak J**, Hsu C, Tuzzio L, Kirlin B, Nekhlyudov L, for the CRN Survivorship Scientific Interest Group. “Providing care for cancer survivors in integrated delivery systems: an assessment of current practices and future opportunities.” Fifth Biennial Cancer Survivorship Research Conference. Washington DC, 2010.
9. Bowles EJA, Buist DSM, **Chubak J**, Yu O, Boudreau DM. “Uptake of tamoxifen and aromatase inhibitors in women with early stage, invasive breast cancer in a community setting, 2001-2008.” American Society of Preventive Oncology. Las Vegas, Nevada, 2011.
10. Pocobelli G, **Chubak J**, Buist D, Hanson N, Drescher C, Resta R, and Urban N. “Rates of prophylactic oophorectomy before and after the introduction of a clinical practice guideline on the referral of high-risk women to genetic counseling.” American Society of Preventive Oncology. Las Vegas, Nevada, 2011.
11. **Chubak J**, Pocobelli G, Weiss NS. “Considerations in developing and using electronic healthcare data algorithms for epidemiologic and health services research.” Congress of Epidemiology. Montreal, Canada, 2011.
12. Boudreau DM, Key D, **Chubak J**. “Comparison of different methods for calculating medication exposure.” International Congress of Pharmacoepidemiology. Chicago, Illinois, 2011.
13. **Chubak J**, Bogart A, Laing S, Green B. “Comparing uptake of fecal occult blood tests for colorectal cancer screening: results from a randomized controlled trial.” American Society of Preventive Oncology. Washington DC, 2012. *Poster received honorable mention.*
14. **Chubak J**, Bogart A, Laing S, Green B. “Comparing uptake of fecal occult blood tests for colorectal cancer screening: results from a randomized controlled trial.” International Cancer Screening Network. Sydney, Australia, 2012.
15. **Chubak J**, Hubbard R, Kamineni A, Wernli K, Rutter R. “Defining and calculating measures of screening participation for international comparative effectiveness research.” International Cancer Screening Network. Sydney, Australia, 2012.
16. **Chubak J**, Rutter CM, Kamineni A, Johnson EA, Stout NK, Weiss NS, Doria-Rose VP, Doubeni CA, Buist DSM. “Relative effectiveness measures: defining and understanding the essential features for comparative effectiveness research.” International Cancer Screening Network. Sydney, Australia, 2012.

17. **Chubak J** and Flaherty L. “Oncology Nurse Navigator Trial.” Group Health Research Rounding. Seattle, Washington, 2013.
18. Ludman E, Bowles E, Rutter C, **Chubak J**, Penfold R, Reid R, McCorkle R, Wagner E. Newly diagnosed cancer patients with and without depressive symptoms benefit from nurse navigation. American Psychosocial Oncology Society. Tampa, Florida, 2014.
19. Burnett-Hartman AN, **Chubak J**, Kamineni A, Ziebell R, Upton MP, Zhu L-C, Newcomb A. Short-term risk of colorectal cancer in colonoscopy patients with sessile serrated polyps. American Society of Preventive Oncology. Arlington, Virginia, 2014.
20. **Chubak J**, Ziebell R, Hart G, Greenlee R, Honda S, Hornbrook M, Lamerato L, Mazor K, Nekhlyudov L, Pawloski P, Ritzwoller D, Quinn V, Doria-Rose VP, Kushi L. “Cancer Research Network: Data availability pre- and post- cancer diagnosis.” HMO Research Network Conference. Phoenix, Arizona, 2014.
21. Halgrim SR, Sizemore L, Pham E, Gundersen G, Carrell DS, Wernli K, **Chubak J**, Rutter CM. “Linking adenomas between colonoscopy and pathology notes for PROSPR.” American Medical Informatics Association. Washington, DC, 2014.
22. Ziebell R, Hart G, **Chubak J**, Krajenta R, Lamerato L, Miroschnik I, Nekhlyudov L, DeFor L, Pawloski P, Tabano D, Ritzwoller D, Wong C, Schmidt M, Rust M, Hornbrook MC, Ghai N, Quinn V, McManus V, Greenlee R, Fouayzi H, Epstein M, Lee V, Kushi L. “Colorectal cancer data in the Cancer Research Network.” HMO Research Network Conference. Long Beach, California, 2015.
23. **Chubak J**, Garcia M, Burnett-Hartman A, Zheng Y, Halm EA, Corley DA, Kamineni A, Singal AG, Green BB, Doubeni CA, Klabunde CN, Rutter CM. “Factors associated with time to colonoscopy after a positive fecal occult blood test.” American Society of Preventive Oncology. Birmingham, Alabama, 2015.
24. Hubbard RA, Ripping TM, **Chubak J**, Miglioretti DM, Broeders MJM. “Accounting for censoring in estimation of cumulative risk of false-positive screening mammography results using observational data.” International Cancer Screening Network. Rotterdam, the Netherlands, 2015.
25. Wernli KJ, Hubbard RA, Johnson E, **Chubak J**, Kamineni A, Green BB, Rutter CM. “Patterns of colorectal cancer screening uptake in newly-eligible men and women.” International Cancer Screening Network. Rotterdam, the Netherlands, 2015.
26. Nekhlyudov L, Walker R, Ziebell R, Rabin B, Nutt S, **Chubak J**. “Cancer survivors’ experiences with insurance, personal finances, and employments: results from a multi-site study.” American Society of Clinical Oncology. Chicago, Illinois, 2015.
27. Ziebell R, **Chubak J**, Vilck Y, Stout N, DeFor T, Pawloski P, Krajenta R, Neslund-Dudas C, Frankland T, Schmidt M, O’Keeffe-Rosetti M, McMullen C, Tabano D, Ritzwoller DP, Lee V, Kushi LH, Hoch B, Greenlee R, Fouayzi H, Epstein MM. “Myeloma Data in the Cancer Research Network” Health Care Systems Research Network Conference. Atlanta, Georgia, 2016.
28. **Chubak J**, Ziebell R, Aiello Bowles EJ, Sterrett A, Ritzwoller DP, Boudreau DM, Yu O, Fujii MM, Boggs JM, Hubbard RA. “Comorbidity prevalence in newly diagnosed colorectal cancer patients.” 8<sup>th</sup> Biennial Cancer Survivorship Research Conference. Washington DC, 2016.
29. Pocobelli G, Ziebell R, Fujii M, McClure J, **Chubak J**. “Symptom burden in long-term head and neck cancer survivors.” Cancer Survivorship Symposium. San Diego, California, 2017.
30. Ziebell R, **Chubak J**, Hartzel D, Rahm A, Malek S, Stout N, DeFor T, Pawloski PA, Krajenta R, Neslund-Dudas C, Mor J, Pishchalenko V, O’Keeffe-Rosetti M, McMullen C, Tabano D, Ritzwoller

D, Laurent C, Kushi LH, Hoch B, Greenlee R, Fouayzi H, Epstein MM. “Adolescent and Young Adult Cancer Data in the Cancer Research Network.” Health Care Systems Research Network Conference. San Diego, California, 2017.

31. Chen L, **Chubak J**, Boudreau DM, Barlow WE, Weiss NS, Li CI. “Diabetes treatments and risks of adverse breast cancer outcomes among early stage breast cancer patients: A SEER-Medicare analysis.” Health Care Systems Research Network Conference. San Diego, California, 2017.
32. Dickerson JF, **Chubak J**, Rabin B, Nekhlyudov, Varga AM, Fujii M, Ziebell R, Banegas MP. The association between employment changes and healthcare use in the year after cancer diagnosis. *Journal of Clinical Oncology*. 2017;35(15\_suppl):6551-6551. American Society of Clinical Oncology. Chicago, Illinois, 2017.
33. Burnett-Hartman AN, Powers JD, **Chubak J**, Corley DA, Ghai NR, McMullen CK, Pawloski PA, Feigelson HS. Tumor characteristics and treatment in early-onset colorectal cancer. ASCO Gastrointestinal Cancers Symposium. San Francisco, California, 2018.
34. Burnett-Hartman AN, **Chubak J**, Hua X, Kamineni A, Ziebell R, Hardikar S, Newcomb PA. The association between sessile serrated adenomas/polyps and subsequent advanced colorectal neoplasia. *Digestive Disease Week*. Washington DC, 2018.
35. Bowles EJ, Yu O, Ziebell R, Chen L, Boudreau D, Ritzwoller DP, Hubbard R, Boggs J, Burnett-Hartman A, Sterrett A, Fujii M, **Chubak J**. Cardiovascular medication use and risks of colon cancer recurrences and second cancers. American Society for Preventive Oncology, New York, NY, March 2018; and Kaiser Permanente National Oncology Symposium, San Francisco, California, 2018.
36. Clarke CL, Kushi LH, **Chubak J**, Pawloski PA, Bulkley JE, Epstein MM, Burnett-Hartman AN, Powell, Pearce CL, Spencer Feigelson H. Age, stage and depression are important predictors of long-term survival among HGSOE patients. 12<sup>th</sup> Biennial Ovarian Cancer Research Symposium. Seattle, Washington, 2018.
37. Reding KW, Cheng RK, Aragaki A, Limacher M, Hundley WG, D’Agostino Jr RD, Chen C, **Chubak J**, Chow EJ, Smoller S, Jackson R, Habel L, Banegas MP, Morgenroth A, Brasky T, Barrington WE, Barac A. Cardiovascular outcomes in relation to use of anti-hypertensive medications in those with and without cancer. 2018 Global Cardio-Oncology Summit. Tampa, Florida, 2018.
38. Green BB, Anderson ML, **Chubak J**, Fuller S, Meenan RT, Vernon SW, Cook AJ. A centralized mailed program and stepped increases of support increases time in compliance with colorectal cancer screening guidelines over 9 years: a randomized trial. Health Care Systems Research Network Conference. Portland, Oregon, 2019.
39. Hua X, Newcomb PA, **Chubak J**, Malen RC, Ziebell R, Kamineni A, Zhu LC, Upton MP, Wurscher MA, Thomas SS, Newman H, Hardikar S, Burnett-Hartman AN. Association between molecular characteristics of serrated polyps and subsequent advanced colorectal neoplasia. American Association for Cancer Research Annual Meeting. Atlanta, Georgia, 2019.
40. Doria-Rose VP, Kamineni A, Breslau ES, **Chubak J**, Corley DA, Doubeni CA, Greenlee RT, Haas JS, Honda SA, Li CI, Marcus PM, Neslund-Dudas C, Ritzwoller DP, Schottinger JE, Skinner CS, Tiro JA, Zheng Y, Beaver EF. “The PROSPR Network: an initiative for studying cancer screening in U. S. community settings.” International Cancer Screening Network Meeting. Rotterdam, the Netherlands, 2019.
41. Kamineni A, Silver MI, Garcia MP, Chao CR, Winer RL, Silverberg MJ, **Chubak J**, Tiro JA, Wheeler CM, Mao C, Corley DA, Doria-Rose VP, Feldman S, Beaver EF. Cervical cancer screening

initiation by HPV status in 4 US healthcare systems. International Cancer Screening Network Meeting. Rotterdam, the Netherlands, 2019.

42. Chen L, **Chubak J**, Yu O, Pocobelli G, Ziebell RA, Aiello Bowles EJ, Fujii MM, Sterrett AT, Boggs JM, Burnett-Hartman AN, Ritzwoller DP, Hubbard RA, Boudreau DM. Changes in use of opioid therapy after colon cancer diagnosis: a population-based study. Society for Epidemiologic Research Annual Meeting. Minneapolis, Minnesota, 2019.
43. Abrahão R, Brunson A, Li Q, Ruddy K, **Chubak J**, Ryder R, Li J, Nichols H, Gray M, Sauer C, Hahn E, Wun T, Keegan T. Endocrine diseases incidence in survivors of adolescent and young adult cancer: A Population-Based Report from the VOICE study. 5<sup>th</sup> Global Adolescent and Young Adult Cancer Congress. Long Beach, California, 2023.
44. Wernli KJ, Haupt EC, Chawla N, Osuji T, Shen E, Smitherman A, Kirchhoff AC, Casperson M, Zebrack BJ, Keegan TMH, Kushi LH, Baggett C, Kaddas H, Ruddy KJ, Sauder C, Wun T, Figueroa Gray M, **Chubak J**, Nichols HB, Hahn EE. Emergency department use in adolescent and young adult cancer survivors: opportunities to improve survivorship care. 5<sup>th</sup> Global Adolescent and Young Adult Cancer Congress. Long Beach, California, 2023.
45. Abrahão R, Li Q, Brunson A, **Chubak J**, Nichols HB, Chao C, Li J, Ruddy K, Sauer C, Malogolowkin M, Kushi L, Hahn E, Wernli K, Wun T, Keegan T. Late venous thromboembolism in adolescent and young adult cancer survivors: a population-based analysis from the VOICE study. 5<sup>th</sup> Global Adolescent and Young Adult Cancer Congress. Long Beach, California, 2023.
46. Hahn EE, Haupt EC, Osuji T, Shen E, Kirchhoff AC, Moy L, Casperson M, Smitherman A, Zebrack BJ, Chubak J, Keagan THM, Kushi LH, Chawla N, Wernli KJ. Post-treatment care for survivors of adolescent and young adult (AYA) cancers: A retrospective cohort analysis of oncology and primary care. 5<sup>th</sup> Global Adolescent and Young Adult Cancer Congress. Long Beach, California, 2023. Winner: Science Poster Award.
47. **Chubak J**, Ichikawa L, Merchant S, Dalmat R, Ziebell R, Jensen C, Lee J, Levin TR, Corley D, Ghai N, Green BB, Skinner CS, Breslau E, Kamineni A. Incidence of harms following colorectal cancer screening by colonoscopy in older adults. Society for Epidemiologic Research Annual Meeting. Portland, Oregon, 2023.
48. Del Vecchio NJ, **Chubak J**, Rendle KA, Halm E, Zheng Z, Winer RL, Silver MI, Corley DA, Greenlee RT, Carroll NM, Haas J, Li CI, Burnett-Hartman AN. Association between screening patterns and stage at cancer diagnosis. International Screening Network (ICSN) Meeting. Turin, Italy, 2023.
49. **Chubak J**, Ichikawa L, Merchant S, Dalmat R, Ziebell R, Jensen C, Lee J, Levin TR, Corley D\*, Ghai N, Green BB, Skinner CS, Breslau E, Kamineni A. Incidence of harms following colorectal cancer screening by colonoscopy in older adults. International Screening Network (ICSN) Meeting. Turin, Italy, 2023. \*Presenter
50. Doria-Rose VP, Ziebell R, Kamineni A, **Chubak J**, Kim RY, Burnett-Hartman AN, Elston Lafata J, Guzman P, Tiro J, Todd K, Zheng Y, Vachani A, Croswell J. The association between time to follow-up testing after a positive screening examination and diagnostic findings. International Screening Network (ICSN) Meeting. Turin, Italy, 2023.
51. Rendle K, Del Vecchio N, Winder R, Zheng Y, **Chubak J**, Pocobelli G, Todd K, Tiro J, Carroll N, Corley D, Halm E, Ghai N, Balasubramanian B, Kamineni A, Kobrin S, Doria-Rose VP. Defining the denominator in membership-based systems: Implications for calculating and comparing cancer

screening uptake in opportunistic and organized settings. International Screening Network (ICSN) Meeting. Turin, Italy, 2023.

52. Dang T, Rieu-Werden M, Kobrin SC, Tiro JA, Lykken JM, Chubak J, Atlas SJ, Higashi RT, Lee SC, Haas JS, Sugg Skinner C, Silver MI, Feldman S. Are providers confident in their knowledge of management guidelines for abnormal cervical cancer screening results? North American Primary Care Research Group. 51<sup>st</sup> Annual Meeting. San Francisco, California, 2023.
53. Nair R, Hu E, Murphy CC, **Chubak J**, Levin TR, Skinner CS, Lui P-H, Halm E. Incomplete colonoscopy: prevalence, factors, and follow-up. Annual Meeting, Washington DC, 2024.
54. Rathod R, Hu E, Pruitt S, Tiro JA, **Chubak J**, Haas J, Atlas SJ, Kruse G, Hughes AE. Association of multi-level factors with cervical cancer screening in healthcare settings [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6\_Suppl):Abstract nr 3451.
55. Chen A, Bowles EJA, **Chubak J**, Cosentino S, Genkinger J, Levine DA, Tehranifar P, Wolfova K, Tom SE. The relationship between cancer diagnosis timing and cognition in older adults in the National Health and Nutrition Examination Survey. Alzheimer's Association International Conference. Philadelphia, Pennsylvania, 2024.
56. Snead C, O'Banion E, Gambatese R, Chao C, Brown M, Green B, Chubak J, White L, Feigelson H, Honda S, Okwandu I, Lin J, Ngo-Metzger Q. Understanding the relationship between social needs and cervical cancer screening. 52<sup>nd</sup> North American Primary Care Research Group Annual Meeting. Quebec City, Quebec, Canada, 2024.
57. Snead C, O'Banion E, Gambatese R, Chao C, Brown M, Green B, Chubak J, White L, Feigelson H, Honda S, Okwandu I, Lin J, Ngo-Metzger Q. Understanding the relationship between social needs and cervical cancer screening. 2<sup>nd</sup> Student Scholarship Symposium. Kaiser Permanente School of Medicine 2024 Student Scholarship Symposium. Pasadena, California, 2024.
58. Abrahão R, Ruddy KJ, Laurent CA, Chubak J, Haupt EC, Brunson A, Hahn EE, Chao C, Moy LM, Wun T, Keegan THM, Sauder CAM. Is trastuzumab associated with new-onset hypertension in adolescents and young adults with breast cancer? San Antonio Breast Cancer Symposium. San Antonio, Texas, 2024. *the Clin Cancer Res* (2025) 31 (12\_Supplement): P2-01-03.
59. Parker K, Heneghan MB, Li QW, Brunson A, Ou JY, Kaddas HK, Abrahão R, **Chubak J**, Wernli KJ, Hahn EE, Zebrack B, Kushi LH, Nichols HB, Keegan THM, Kirchhoff AC. Exploring Patterns of Late Effects among Adolescent and Young Adult Hodgkin Lymphoma Survivors in the Valuing Opinions and Insight from Cancer Experiences (VOICE) Study. Frontiers Symposium on Transformation in Cancer Care Delivery. Salt Lake City, Utah, 2025.
60. Halm EA, Del Vecchio NJ, Rendle KA, Tiro JA, Zheng Y, Winer RL, Haas JS, Corley DA, Skinner CS, Schottinger J, Ghai NR, **Chubak J**. Longitudinal adherence to screening for colorectal, cervical, and lung cancer in 10 regional health systems in the US national PROSPR cancer research consortium. International Cancer Screening Network Conference. Aarhus, Denmark, 2025.
61. Halm E, Nair R, Skinner CS, Hu E, Green BB, Jensen C, Levin TR, Schottinger J, Ghai N, **Chubak J**. Long term patterns and predictors of repeat fecal immunochemical testing for colorectal cancer screening in four regional US health systems. International Cancer Screening Network Conference. Aarhus, Denmark, 2025.
62. Abrahão R, Smitherman A, Sauder C, Ruddy K, Nichols H, **Chubak J**, Kirchhoff A, Kushi L, Hahn E, Keegan T. Incidence of chronic medical conditions in adolescent and young adult survivors of

hematologic malignancies in California, 2006–2020. EACR25-1701. *Molecular Oncology* 19 (Suppl. 1) (2025) p 581-582. Presented at the Annual Congress of the European Association for Cancer Research. Lisbon, Portugal, 2025.

63. Abrahão R, Smitherman A, Sauder C, Ruddy K, Nichols H, Chubak J, Kirchoff A, Kushi L, Hahn E, Keegan T. Incidence of chronic medical conditions in adolescent and young adult survivors of hematologic malignancies in California, 2006–2020. *Health Disparities in Hematologic Malignancies Conference*. New York, 2025.
64. Del Toro Rivera D, Li Q, Kirchoff AC, Abrahão R, Brunson A, **Chubak J**, Hahn EE, Chao C, Nichols HB, Sauder CA, Ruddy KJ, Keegan THM. Late Effects in Adolescent and Young Adult Survivors of Colorectal. *UC Davis Comprehensive Cancer Center Annual Cancer Research Symposium*. Lisbon, Portugal, 2025.
65. Brookes J, Ellington T, Khan A, Waters AR, Kirchoff AC, Jones SMW, Abrahão R, Casperson M, Chao CR, Gray MF, Ruddy KJ, Sauder CAM, Wernli KJ, Chubak J, Hahn EE, Keegan THM, Kushi LH, Nichols HB. Use of fertility cryopreservation strategies and financial hardship among AYA cancer survivors. *Adolescent and Young Adult Cancer Coalition (AYACC) Conference*. Chapel Hill, North Carolina, 2025.

## SEMINARS

1. “Endometrial cancer risk in former users of unopposed estrogens: The influence of switching to combined estrogen-progestin therapy.” Fred Hutchinson Research Center. June 16, 2006.
2. “Determining date of death in women with breast cancer.” Breast Cancer Surveillance Scientific Meeting, Group Health Center for Health Studies. December 6, 2006.
3. “Selected methodological issues in pharmacoepidemiological studies.” Group Health Center for Health Studies. June 5, 2007.
4. “Medicare Special Needs Program Evaluation.” Group Health. January 16, 2008.
5. “Cost of false positive mammograms,” Breast Cancer Surveillance Scientific Meeting, Group Health Research Institute. June 29, 2009.
6. “Algorithms to Identify Second Breast Cancer Events from Electronic Data,” Group Health Research Institute. January 19, 2010.
7. “Fecal Occult Blood Testing - Is it FIT for large-scale population based screening? Results from a randomized trial and matched cohort study” (co-presenter) Alliance for Reducing Cancer, Northwest. December 8, 2011.
8. “Algorithms to identify second breast cancer events from administrative data,” Women’s Health Initiative Survivor Cohort Committee Meeting, Fred Hutchinson Cancer Research Center. May 3, 2013.
9. “Methodological issues in studies of cancer recurrence and mortality.” Joint Cancer Prevention/Epidemiology Seminar Series, Fred Hutchinson Cancer Research Center. January 31, 2014.
10. “The cat is out of the bag: preliminary findings from studies of animal-assisted activities in pediatric oncology.” Group Health Research Institute Scientific Seminar. April 26, 2016.
11. “Survivorship research within the Cancer Research Network.” Long Term Effects and Survivorship Affinity Group, Fred Hutchinson Cancer Research Center. May 12, 2016.

12. “Therapy Dog Visits for Children with Cancer: A Randomized Controlled Trial of Psychological Effects and Pathogen Transmission.” Washington State Department of Health. April 17, 2018.
13. “Bias in pharmacoepidemiologic studies of cancer outcomes: a case study.” UNC Pharmacoepidemiology Seminar. February 11, 2019.
14. “Using electronic health data for cancer research.” The Data of Cancer Research Seminar Series, Fred Hutchinson Cancer Research Center. July 22, 2019.
15. “Long-term adherence to colorectal cancer screening over 9 years in the Systems of Support to Increase Colorectal Cancer Screening Trial (SOS).” Co-presented with Dr. Beverly B. Green. Clinical Trials Affinity Group, Fred Hutchinson Cancer Research Center. December 19, 2019.
16. “Using electronic health records for research: an overview of considerations.” The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington. April 8, 2020.
17. “Race and ethnicity in analyses of health care data: reflections from KPWHRI researchers.” Co-organizer and co-presenter with Regan Gray, Rebecca Ziebell, Maricela Cruz, and Yates Coley. Kaiser Permanente Washington Health Research Institute Seminar. September 7, 2021.
18. “Measurement challenges in cancer research with healthcare data.” Kaiser Permanente Washington Health Research Institute Seminar. April 22, 2025.

## **TEACHING**

### **Formal courses**

Tutor (Lecturer), “Patient, Doctor, and Society,” University of Otago, New Zealand, 2001 – 2002  
 Teaching Assistant, “Epidemiologic Methods,” University of Washington, 2006 – 2007  
 Co-instructor, “Introduction to Epidemiology,” University of Washington, Autumn 2021  
 Instructor, “Clinical Epidemiology,” University of Washington, Spring 2024 & 2025

### **Guest lecturer/instructor**

Case study discussion co-leader “Research Ethics,” Fred Hutchinson Cancer Research Center, 2005.  
 Lecturer, “Epidemiology 101,” Group Health Center for Health Studies, 2007.  
 Lecturer, “Marginal Structural Models,” University of Washington, Pharmacoepidemiology, 2008.  
 Session leader, Epidemiology journal club, University of Washington, 2009.  
 Lecturer, “Cancer as a chronic disease: managing care for cancer survivors.” Oncology symposium for the primary care team, Seattle Cancer Care Alliance, 2013.  
 Lecturer, “Epidemiology 101,” Group Health Research Institute, 2015.  
 Instructor, “Exploring Bias and Threats to Validity in Studies of Cancer Recurrence and Survival” in “Applying Epidemiologic Methods for Observational Data in Survivorship Research.” 8<sup>th</sup> Biennial Cancer Survivorship Research Conference, 2016.  
 CME Faculty, “Colorectal Cancer Screening Guideline Update,” Medical Staff Video Conference Series, Group Health, 2016.  
 Lecturer, “Randomized Controlled Target Trial Emulation,” Epidemiology 533 (Pharmacoepidemiology), University of Washington, 2020, 2022, and 2024.  
 Lecturer, “Exploring Bias and Threats to Validity in Studies of Cancer Recurrence and Survival,” Epidemiology 582 (Design and Analytic Strategies to Enhance the Validity of Epidemiologic Studies), University of Washington, 2017-2025.

Lecturer, “Epidemiology 101,” Kaiser Permanente Washington Health Research Institute, 2019.

## **Organization**

Co-organizer, (Course) “Epidemiology 101,” Group Health Research Institute, 2015.

Co-organizer, (Workshop) “Applying Epidemiologic Methods for Observational Data in Survivorship Research.” 8th Biennial Cancer Survivorship Research Conference, 2016.

Co-organizer, (Course) “Epidemiology 101,” Kaiser Permanente Washington Health Research Institute, 2019.

## **ADVISING AND FORMAL MENTORING**

### **PhD committees in chair roles**

Chair, Doctoral Committee for Ronit Dalmat, Department of Epidemiology, University of Washington, 2019 – 2022. “Cumulative Risk of Colorectal Cancer and Colorectal Cancer Mortality in Screen-Eligible Older Adults with History of Adequate Screening.”

### **PhD committees in non-chair roles**

Member, Doctoral Committee for Sarah Lowry, Department of Epidemiology, University of Washington, 2009 – 2012. “Risk of non-Hodgkin Lymphoma in Relation to Tricyclic Antidepressant Use.”

Member, Doctoral Committee for Lu Chen, Department of Epidemiology, University of Washington, 2014 – 2016. “Hypertension and diabetes treatment and risk of adverse outcomes among breast cancer patients.”

Member and Graduate School Representative, Committee for Emily Ahrens, School of Nursing, University of Washington, 2022 – 2025.

### **Masters committee in non-chair roles**

Member, Masters Committee for Sophie Mayer, Department of Epidemiology, University of Washington, 2016. “CYP2D6 inherited variation and inhibiting medication use in relation to adverse breast cancer outcomes after tamoxifen therapy.”

### **External examiner**

External examiner, School of Public Health, University of Alberta, Canada, 2024.

### **Supervision and mentoring**

Research Assistant Supervisor, Gaia Pocobelli, MSc; PhD student in Epidemiology, University of Washington, School of Public Health, 2009 – 2011

Student Intern Supervisor, David Liss, MA, PhD student in Health Services, University of Washington, School of Public Health, 2009 – 2010

Faculty Supervisor. Supervised faculty members (scientists), Kaiser Permanente Washington Health Research Institute, 2009 – present

2009-2012: 1 direct report

2013: 0 direct reports

2014: 1 direct report

2015-2019: 2 direct reports

2020-2022: 7 direct reports

2023: 6 direct reports

2024: 5-8 direct reports

2025: 5-8 direct reports

2026: 6 direct reports

Cancer Research Network (CRN) Scholars mentoring committee member

Dr. Dori Rosenberg, PhD, Group Health Research Institute, 2013 – 2015

Dr. Amit Singal, MD, MPH, University of Texas Southwestern, 2013 – 2015

Dr. Kim Danforth, PhD, Kaiser Permanente Southern California, 2015 – 2017

Other mentoring

Dr. Salene M.W. Jones, Group Health Research Institute, 2014 – 2015

Ms. Erin J. Aiello Bowles, MPH, Kaiser Permanente Washington Health Research Institute, 2016 – present

Dr. Lu Chen, PhD, Kaiser Permanente Washington Health Research Institute, 2018 – 2019

Dr. Ellen O’Meara, PhD, Kaiser Permanente Washington Health Research Institute, 2014 – 2025

Dr. Gaia Pocobelli, PhD, Kaiser Permanente Washington Health Research Institute, 2015 – present

Dr. Aruna Kamineni, PhD, Kaiser Permanente Washington Health Research Institute, 2018 – 2023

Dr. Meagan Brown, PhD, Kaiser Permanente Washington Health Research Institute, 2023 – present